Protocol I8F- MC-GPGM  (b) 
 
Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and  Increased Cardiovascular Risk (SURPASS -4) 
 [STUDY_ID_REMOVED] 
Approval Date: 10-Jul-2020 
I8F-MC-GPGM(b) Clinical Protocol Page 1
LY3298176Protocol I8F-MC-GPGM (b)
Efficacy  and Safety  of LY3298176 Once Weekly  versus 
Insulin Glargine in Patients with Ty pe 2 Diabetes and 
Increased Cardiovascular Risk (SURPA SS-4)
2018 -002618 -11
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distr ibuted to persons not involved in the clinical investigation of 
LY3298176 , unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries .  
Note to Regulatory Authorities:   This document may contain protected p ersonal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, this document is subject to Freedom of Inf ormation Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY3298176 
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed a nd Approved by Lilly : 18JUL2018
Amendm ent (a) Electronically Signed and Approved by Lilly : 28Sep2018
Amendm ent (b) Electronically Signed and Approved by Lilly on approval date provided 
below: 
Approval Date: 10-Jul-2020 GMT
I8F-MC-GPGM(b) Clinical Protocol Page 2
LY3298176Table of Contents
Section Page
Protocol  I8F-MC-GPGM(b) Efficacy  and Saf ety of LY3298176 Once 
Weekly versus Insulin Glargine in Pat ients with Type 2 Di abetes and 
Increased Cardiovascular Risk (SURPASS -4)..................................................................... 1
Table of Contents ........................................................................................................................ 2
1. Synopsis ............................................................................................................................. 9
2. Schedule of Act ivities....................................................................................................... 13
3. Introduction ................................
...................................................................................... 23
3.1. Study  Rati onale ............................................................................................................ 23
3.2. Background .................................................................................................................. 23
3.3. Benefit/Risk Assessment .............................................................................................. 24
4. Object ives and Endpo ints.................................................................................................. 25
5. Study  Design ..................................................................................................................... 27
5.1. Overall Desig n............................................................................................................. 27
5.2. Number of Participants .................................................................................................31
5.3. End of Study  Definit ion............................................................................................... 31
5.4. Scientific Rationale for Study  Design ........................................................................... 31
5.5. Justification for Dose ................................................................................................... 31
6. Study  Popul ation............................................................................................................... 33
6.1. Inclusio nCriteria.......................................................................................................... 33
6.2. Exclusio n Cri teria........................................................................................................ 35
6.3. Lifes tyle Restrict ions.................................................................................................... 37
6.4. Screen Failures ............................................................................................................. 38
7. Treatments ........................................................................................................................ 39
7.1. Treatments Admi nistered ............................................................................................. 39
7.1.1. Packaging and Labeling ....................................................................................... 40
7.1.2. Medical Devices ................................................................................................... 40
7.2. Metho d of Treatment Assignment ................................................................................ 40
7.2.1. Selection and Timing o f Doses ............................................................................. 40
7.2.1.1. LY3298176 .................................................................................................... 40
7.2.1.2. Insulin Glargine .............................................................................................. 40
7.3. Blinding ....................................................................................................................... 41
7.4. Dosage Modification .................................................................................................... 41
7.4.1. Study  Drugs ......................................................................................................... 41
I8F-MC-GPGM(b) Clinical Protocol Page 3
LY32981767.4.2. Reducti on and/or Discont inuat ion of Conco mitant 
Antihyperglycemic Medicat ions........................................................................... 41
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 42
7.6. Treatment Compliance .................................................................................................42
7.7. Concomitant Therapy ................................................................................................... 43
7.7.1. Management of Patients with Gastrointestinal Symptoms ..................................... 43
7.8. Treatment after the End of the Study ............................................................................ 44
7.8.1. Treatment after Study  Com pletion........................................................................ 44
7.8.2. Speci al Treatm ent Consi derat ions........................................................................ 45
8. Discontinuati on Cri teria .................................................................................................... 46
8.1. Discontinuati on from Study  Treatm ent......................................................................... 46
8.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 46
8.1.2. Temporary  Interrupti on of  Study  Treatm ent......................................................... 47
8.1.3. Discontinuati on of  Inadvertent ly Enrolled Patients ............................................... 47
8.2. Discontinuati on from the Study .................................................................................... 47
8.3. Lost to Follow -up......................................................................................................... 48
9. Study  Assessments and Procedures ................................................................................... 49
9.1. Efficacy Assessments ................................................................................................... 49
9.1.1. Primary Efficacy Assessments and Procedures ..................................................... 49
9.1.2. Secondary  Efficacy  Assessments and Procedures ................................................. 49
9.1.3. Exploratory  Efficacy  Assessments and Procedures ............................................... 49
9.1.4. Appropriateness of Assessments .......................................................................... 50
9.2. Adverse Events ............................................................................................................ 50
9.2.1. Serious Adverse Events ........................................................................................ 51
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 52
9.2.2. Adverse Events of Special Interest ....................................................................... 52
9.2.2.1. Hypoglycemia ................................................................................................ 52
9.2.2.2. Severe, Persistent Hy perglycemia ................................................................... 53
9.2.2.3. Pancreat itis..................................................................................................... 54
9.2.2.4. Thyroid Malignancies and C -Cell Hyperplasia ................................................ 55
9.2.2.5. Major Adverse Cardio vascular Events ............................................................ 56
9.2.2.6. Supraventricular Arrhyt hmias and Cardiac Conduction 
Disorders ........................................................................................................ 56
9.2.2.7. Hypersensi tivity Events .................................................................................. 56
9.2.2.7.1. Inject ion Site Reacti ons ............................................................................ 56
9.2.2.7.2. Anti-Drug Ant ibodies ............................................................................... 56
9.2.2.8. Diabetic Ret inopathy  Com plicat ions............................................................... 57
9.2.2.9. Hepatobiliary  Disorders .................................................................................. 57
I8F-MC-GPGM(b) Clinical Protocol Page 4
LY32981769.2.2.10. Severe Gastrointestinal Adverse Events .......................................................... 57
9.2.2.11. Acute Renal Events ........................................................................................ 57
9.2.2.12. Metabo lic Acidosis, Including Diabetic Ketoacidosis ..................................... 57
9.2.2.13. Amputati on/Peri pheral Revascularizat ion....................................................... 58
9.2.2.14. Major Depressive Disorder/Suicidal Ideat ion.................................................. 58
9.2.3. Com plaint Handling ............................................................................................. 58
9.3. Treatment of Overdose .................................................................................................58
9.4. Safety........................................................................................................................... 58
9.4.1. Electrocardiograms .............................................................................................. 58
9.4.2. Vital Signs ........................................................................................................... 59
9.4.3. Laboratory  Tests .................................................................................................. 59
9.4.4. Immunogenicit y Assessments .............................................................................. 59
9.4.5. Safety Moni toring ................................................................................................ 60
9.4.5.1. Hepati c Safet y Moni toring .............................................................................. 60
9.5. Pharmacokinet ics......................................................................................................... 60
9.6. Pharmacodynamics ...................................................................................................... 61
9.7. Pharmacogeno mics ...................................................................................................... 61
9.7.1. Who le Blood Samples for Pharmacogenet ic Research .......................................... 61
9.8. Biomarkers ................................................................................................................... 61
9.9. Heal th Economics ........................................................................................................ 62
9.9.1. European Qualit y of Life (EQ -5D- 5L).................................................................. 62
9.9.2. Abilit y to Perform  Physical Act ivities of Daily Living 
(APPADL) ........................................................................................................... 63
9.9.3. Impact of Weight on Self -Percept ion Quest ionnaire (IW -SP)............................... 63
9.9.4. Diabetes Treatm ent Satisfaction Questionnaire (DTSQ) ....................................... 63
10. Statistical Considerations .................................................................................................. 64
10.1. Sample Si ze Determinat ion.......................................................................................... 64
10.2. Popul ations for Analyses .............................................................................................. 65
10.3. Statistical Analyses ...................................................................................................... 65
10.3.1. General Statist ical Considerat ions........................................................................ 65
10.3.2. Treatment Group Comparabilit y........................................................................... 66
10.3.2.1. Patient Disposi tion.......................................................................................... 66
10.3.2.2. Patient Characterist ics.................................................................................... 66
10.3.2.3. Concomitant Therapy ..................................................................................... 66
10.3.2.4. Treatment Compliance .................................................................................... 67
10.3.3. Efficacy Analyses ................................................................................................ 67
10.3.3.1. Primary Analyses ........................................................................................... 67
10.3.3 .2. Secondary  Analyses ........................................................................................ 68
I8F-MC-GPGM(b) Clinical Protocol Page 5
LY329817610.3.3.3. Terti ary/Exploratory  Analyses ........................................................................ 68
10.3.4. Safety Analyses .................................................................................................... 68
10.3.4.1. Hypoglycemic Events ..................................................................................... 69
10.3.4.2. Gastrointestinal Events ................................................................................... 69
10.3.4.3. Adjudicated Cardiovascular Events ................................................................ 69
10.3.4.4. Central  Laboratory  Measures, Vi tal signs, and 
Electrocardiograms ......................................................................................... 69
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 69
10.3.6. Evaluat ion of Immunogenicit y............................................................................. 70
10.3.7. Other Analyses ..................................................................................................... 70
10.3.7.1. Health Economics ........................................................................................... 70
10.3.7.2. Subgroup Analyses ......................................................................................... 70
10.3.8 .Interim Analyses .................................................................................................. 70
10.3.8.1. Interim Safet y CV Analysis ............................................................................ 71
11. References ........................................................................................................................ 72
12. Appendices ....................................................................................................................... 74
I8F-MC-GPGM(b) Clinical Protocol Page 6
LY3298176List of Tables
Table Page
Table GPGM.1. Schedule of Act ivities.................................................................................... 14
Table GPGM.2. Object ives and Endpo ints............................................................................... 25
Table GPGM.3. LY3298176 Treatment Regimens .................................................................. 39
Table GPGM.4. Titration of  Insulin Glargine .......................................................................... 41
Table GPGM.5. Descript ion of Analysis Sets .......................................................................... 65
I8F-MC-GPGM(b) Clinical Protocol Page 7
LY3298176List of Figures
Figure Page
Figure GPGM.1. Illustrati on of  study  design for Clinical Protocol I8F -MC-GPGM. ................. 28
I8F-MC-GPGM(b) Clinical Protocol Page 8
LY3298176List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 75
Append ix 2. Clinical Laboratory  Tests ............................................................................... 80
Appendix 3. Study  Governance Considerat ions.................................................................. 82
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 86
Appendix 5. World Heal th Organizat ion Classification of Diabetes and Diagnostic 
Criteria ................................
.......................................................................... 87
Appendix 6 . Classificat ion of Contraceptive Methods ........................................................ 88
Appendix 7. Management of Patients with Severe, Persistent Hyperglycemia during 
the Trea tment Peri od...................................................................................... 89
Appendix 8. Changes to Study  Procedures due to the COVID -19 Pandemic ...................... 90
Appendix 9. Protocol  Amendment I8F -MC-GPGM(b)
Efficacy and Safet y of LY3298176 Once Weekly versus Insulin 
Glargine in Pat ients with Type 2 Di abetes and Increased Cardio vascular
Risk (SURPASS -
4)........................................................................................ 91
I8F-MC-GPGM(b) Clinical Protocol Page 9
LY32981761.Synopsis
Title of Study:
Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and 
Increased Cardiovascular Risk .
Rationale: 
Patients with type 2 diabetes mellitus ( T2DM) need antihy perglycemic treatment. As the disease progresses, 
multiple drug treatments are warranted to manage the disease.  When oral therapies are insufficient to reach targe t 
glycemia, injectable therapies are added.  Basal insulins, such as glargine, are frequently used as the first injectable 
after failure of the oral therapy.  Adequately titrated glargine therapy, in combination with oral treatment, frequently 
achieves the target glycemic level ; however, it is frequently associated with weight increase and eventual 
hypoglycemia.  LY3298176 is a 39 -amino acid synthetic peptide with agonist activity at both the GIP (glucose -
dependent insulinotropic polypeptide) and GLP -1 (glucagon -like peptide -1) receptors.  Its structure is based on the 
GIP sequence and includes a C20 fatty di -acid moiety.  It is administered once weekly (QW) by subcutaneous 
administration. The aim of the present study is to compare the g lycemic effect of glargine and LY3298176 in 
patients with T2DM and elevated risk for cardiovascular disease.  The study willalso compare the effect of these 
drugs on weight and their safety profile.
Study I8F -MC -GPGM (GPGM) is a Phase 3, open -label compar ator, multicenter, parallel -arm, randomized study to 
compare the safety and efficacy of 3 maintenance doses of LY3298176 with insulin glargine in patients with T2DM
with increased cardiovascular (CV) risk. The primary endpoint will be the mean change in hemoglobin A1c 
(HbA1c) levels from baseline to 52weeks.
Objective(s)/Endpoints:
Objectives Endpoints
Primary
To demonstrate that QW LY3298176 10mg
and/o r 15mgis no ninferior to insulin 
glargine for change from baseline in HbA1c
at 52weeksMean change in HbA1c 
Key Secondary (controlled for type 1 error)
Efficacy
Todemonstrate that QW LY3298176 5 mg is 
noninferio r to insulin glargine for change 
from baseline in HbA1c at 52 weeks Mean change in HbA1c 
To demonstrate that QW LY3298176 5mg, 
10 mg, and/or 15mgis superior to insulin 
glargine for change from baseline in weight 
at 52 weeks 
To demonstrate that QW LY3298176 5mg, 
10 mg, and/or 15mgis superior to insulin 
glargine for change from baseline in HbA1c
at 52 week s
To demonstrate that QW LY3298176 5mg, 
10 mg, and/or 15mgis superior to insulin Mean change in body weight 
Mean change in HbA1c 
I8F-MC-GPGM(b) Clinical Protocol Page 10
LY3298176Objectives Endpoints
glargine for the proportion of patients with 
HbA1c target val ues of <7.0% (53 
mmol/mol) at 52 weeksHbA1c
Additional Secondary (not controlled for type 1 
error)
Efficacy
To demonstrate that QW LY3298176 5mg, 
10 mg, and/or 15mg is superior to insulin 
glargine at 52 weeks The mean change in fasting serum glucose
(central laboratory) from baseline
The proportion of patients achieving an HbA1c 
target value of ≤6.5% (48 mmol/mol) and 
<5.7% (39 mmol/mol)
Mean change in 7 -point self -monitored blood 
glucose profiles from baseline
Proportio n of patients who achieved weight 
loss of ≥5%, >10%, and >15% from baseline 
Safety
To compare the safety of LY3298176 5mg, 
10 mg, and 15mg LY3298176 to insulin 
glargine at 52weeks and at the end of the 
safety follow -up period, with respect to the 
following outcomesTreatment -emergent adverse events (TEAEs)
Early  discontinuation s of study drug due to 
adverse events ( AEs)
Adjudicated deaths and nonfatal major CV 
events
Adjudicated pancreatic AEs
Medullary  thyroid carcinoma (MTC), C -cell 
hyperplasia ,and serum calcitonin 
Incidence of treatment -emergent LY3298176
anti-drug antibodies and systemic 
hypersensitivity reactions 
Mean change in systolic and diastolic blood
pressure and heart rate from baseline 
Occur rence of hypoglycemic events
Time to initiation of rescue therapy for severe, 
persistent hyperglycemia
Pharmacokinetics
To characterize the pharmacokinetics (PK) of 
LY3298176 5mg, 10 mg, and 15mg and 
evaluate the relationship sbetween 
LY3298176 exposure and safety, tolerability ,
and efficacy measuresPopulation PK and PD parameters
I8F-MC-GPGM(b) Clinical Protocol Page 11
LY3298176Summary of Study Design:   
Study GPGM is aPhase 3, open -label comparator, multicenter, parallel -arm, randomized study to compare the 
safety and efficacy of 3 maintenance doses of LY3298176 with insulin glargine in patients with T2DM with 
increased CVrisk. The primary en dpoint will be the mean change inHbA1c from baseline to 52weeks. 
Treatment Arms and Duration:   
Patients will be randomized in a 1:1: 1:3ratio to receive 5 mg LY3298176 , 10mg LY3298176 , 15 mg LY3298176 , 
or insulin glargine.  The randomization will be stratified by country, baseline HbA1c concentration ( ≤8.5%, ˃8.5% 
[
≤69, ˃69 mmol/mol]), and sodium -glucose co -transpo rter-2 inhibitors ( SGLT -2i)use ( YesorNo). 
The study  will continue until all of the foll owing criteria are fulfilled.
1) A t least 52 weeks from the time of the last patient randomized 
2)At least 300 patients assigned to the combined LY3298176 arms reach at least 78 weeks of treatment
3)Approximately 110patients in this study experience at least 1 component event of the composite CV 
endpoint of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina
Number of Patients :
Approximately 1878 patients will be randomized in a 1:1: 1:3ratio to 5mg LY3298176 (313 patien ts), 10mg 
LY3298176 (313 patients), 15 mg LY3298176 (313 patients) ,and insulin glargine (93 9patients).  
Statistical Analysis:
Efficacy Analyses :
Efficacy and safety will be assessed using the modified intention -to-treat population, which consists of all randomly 
assigned participants who are exposed to at least 1 dose of study drug. There will be 2 estimands of interest in 
comparing efficacy of LY3298176 doses with insulin glargine relative to the primary measure of mean change in 
HbA1c from baseline to 52-week visit. First estimand, the “efficacy” estimand, represents efficacy prior to 
discontinuation of study drug without confounding effects of rescue therapy for persistent severe hyperglycemia.  
Second estimand, the “ treatment -regimen” estimand, represents the efficacy irrespective of adherence to 
investigational product or introduction of rescue therapy for persistent severe hyperglycemia.
For the FDA, the primary efficacy assessment swill be guided by the “treatment -regimen” estimand .  This 
assessment will analyze change from baseline in HbA1c to 52-week visit using an analysis of covariance 
(ANCOVA) with terms, treatment, stratification factors: country, SGLT -
2i use (Yes or No), andbaseline HbA1c as 
a covariate . The ANCOVA analysis will be conducted using full analysis set (FAS) at 52-week visit, w hich consists 
of all available change from baseline in HbA1c data at the 52
-week visit, irrespective of whether they were obtained 
whilethe participants had discontinued the study drug or whether the participant had been given rescue medication.   
Additionally, data for subjects with missing values will be imputed based on observed data from subjects in the 
same treatment arm who had their efficacy measure at the Week 52visit assessed after early discontinuation of 
study drug and/or initiation of rescue medication (retrieved dropouts).  Analysis will be conducted with multiple 
imputations, and statistical inference over multiple imputations will be guided by the method proposed by Rubin 
(1987).
I8F-MC-GPGM(b) Clinical Protocol Page 12
LY3298176For all other purposes, t he primary efficacy assessment swill be guided by the “efficacy” estimand.  This assessment 
will use efficacy analysis set (EAS) which consists of data obtained bef ore the initiation of any rescue therapy and 
before premature treatment discontinuation. Theanalysis model for change from baseline in HbA1c assessed over 
time will be a mixed model for repeated measures (MMRM), with terms: treatment, visit, and treatment -by-visit 
interaction, stratification factors: country, SGLT -2i use (Yes or No), as fixed effects, and baseline HbA1c as a 
covariate. An unstructured covariance structure will model relationship of within -patient errors.
Since the two estimands are inte nded for different purposes, no multiplicity adjustments will be made. For each 
estimand, the overall type I error rate of primary and key secondary efficacy endpoint assessments relative to each 
estimand will be controlled at 2-sided 0.05 level.  
Additional details, including analysis methods for key secondary endpoints and thestrategy  for controlling overall 
type 1 erro r rate in evaluating primary  and key secondary endpoint evaluation to a 2 -sided 0.05 significance level ,
will be provided in the statistical analysis plan (SAP).
Safety Analyses:
Unless specified otherwise, s afety  assessment swill be based on all available data, irrespective of whether they were 
obtained after the participants had discontinued the study drug or whether the participant had been given rescue 
medication. Summary statistics will be provided for incidence of TEAEs, serious adverse events, and study 
discontinuation due to AEs or death during the treatment period. Counts and proportions of subject s experiencing 
AEs will be reported for each treatment group, and Fisher’s exact test will be used to compare the treatment groups. 
For continuous laboratory analytes, summary statistics will be provided by visit, with statistical comparisons among 
treatm ent at each visit conducted using a nMMRM analysis.  Selected safety analysis ( for example, hypogly cemia) 
will be conducted after excluding data while on rescue therapy.  Additional details, including analysis of AEs of 
special interest, will be provided i n the SAP.
I8F-MC-GPGM(b) Clinical Protocol Page 13
LY32981762. Schedule of A ctivities
The Schedule o f Activities described below should be fo llowed for all pat ients enrolled in 
Study GPG M.  However, for those patients whose participat ion in this study  isaffected by  severe 
acute respiratory  syndrom e coronavi rus 2 ( SARS -CoV -2), the virus that causes the novel 
Coronavirus Disease 2019 (COVID -19), please refer to Appendix 8 for addi tional instructi ons
.
I8F-MC-GPGM(b) Clinical Protocol Page 14
LY3298176Table GPGM .1. Schedule of A ctivities
Study 
Period IStudy Period II
52 WeeksStudy Period III
VariableStudy 
Period 
IV
Screening 
Lead inTreatment PeriodSafety 
F/U
Visit 1 2 3a 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29FT
Vz ETb 801
Week of 
Treatment-3 -2 0 1 2 3 4 5 6 7 8 10 12 15 16 20 23 24 28 32 35 36 42 52 62 72 78 88 1044 week 
post 
end of 
tx
Allowable 
Deviation 
(days)c- ±3 ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 ±3 ±3 - ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±3
Fasting Visitd X X X X X X X X X X X X X X X
PK only Visit X X
Telephone Visit X X X X
Informed 
consentX
RandomizationX
Clinical Assessments
Medical historye X
Physical X X X
Height X X
WeightfX X X X X X X X X X X X X X X X X X X
Waist 
circumferenceX X X X X X X X X X
ECGgX X X X X X X X
Vital signs (2 
sitting BP and 
HR)gX X X X X X X X X X X X X X X X X X X X X X X X X
Dilated 
fundo scopic 
examhX
Adverse eventsX X X X X X X X X X X X X X X X X X X X X X X X X X X X X
Concomitant 
medicationsX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
I8F-MC-GPGM(b) Clinical Protocol Page 15
LY3298176Study 
Period IStudy Period II
52 WeeksStudy Period III
VariableStudy 
Period 
IV
Screening 
Lead inTreatment PeriodSafety 
F/U
Visit 1 2 3a 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29FT
Vz ETb 801
Week of 
Treatment-3 -2 0 1 2 3 4 5 6 7 8 10 12 15 16 20 23 24 28 32 35 36 42 52 62 72 78 88 1044 week 
post 
end of 
tx
Allowable 
Deviation 
(days)c- ±3 ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 ±3 ±3 - ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±3
Fasting Visitd X X X X X X X X X X X X X X X
PK only Visit X X
Telephone Visit X X X X
Hypoglycemic 
events reviewX X X X X X X X X X X X X X X X X X X X X X X X X X X X
Patient Education
Diabetes 
educationI I, j X
BG meter, 
SMBG trainingj X
Dispense BG 
meter/
supplies as 
neededX X X X X X X X X X X X X X X X X X X X X X X
Study drug 
injection 
trainingjX X
Hand out diary 
and instruct on 
useX X X X X
Remind patient 
about 7 -point 
SMBGkX X X
Review 7 -point 
SMBG values 
collected in the 
diaryX X X
Dispense study 
drug X X X X X X X X X X X X X X X X
Observe patient 
Administer 
LY3298176,l,mX
I8F-MC-GPGM(b) Clinical Protocol Page 16
LY3298176Study 
Period IStudy Period II
52 WeeksStudy Period III
VariableStudy 
Period IV
Screening 
Lead inTreatment Period Safety 
F/U
Visit
1 2 3a 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 2324 25 26 27 28 29FT
Vz ETb801
Week of 
Treatment-3 -2 0 1 2 3 4 5 6 7 8 10 12 15 16 20 23 24 28 32 35 36 4252 62 72 78 88 1044 weeks 
post end 
of tx
Allowable 
Deviation 
(days)c- ±3 ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 ±3 ±3 - ±3 ±7±7 ±7 ±7 ±7 ±7 ±7 ±3
Fasting 
VisitdX X X X X X X X XX X X X X X
PK only 
VisitX X
Telephone 
VisitX X X X
Patient 
returns 
study drugs 
and 
injection 
suppliesX X X X X X X X X X X X XX X X X X X X
Assess 
study drug 
compliance X X X X X X X X X X X X X XX X X X X X X X
Review 
insulin dose 
and 
adjustment 
per TTT 
algorithmn,oX X X X X X X X X X X X X X X X X XX X X X X X X
Assess 
compliance 
with insulin 
dose 
adjustment 
TTT 
algorithmoX X X X X X X X X X X X X XX X X X X X X X
I8F-MC-GPGM(b) Clinical Protocol Page 17
LY3298176Study 
Period IStudy Period II
52 WeeksStudy Period III
VariableStudy 
Period IV
Screening 
Lead inTreatment PeriodSafety F/U
  Visit 1 2 3a 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 FTVz
ETb 801
Week of 
Treatment-3 -2 0 1 2 3 4 5 6 7 8 10 12 15 16 20 23 24 28 32 35 36 42 52 62 72 78 88 1044 weeks 
post end of 
tx
Allowable 
Deviation 
(days)c- ±3±
7±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 ±3 ±3 - ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±3
Fasting 
VisitdX X X X X X X X X X X X X X X
PK only 
VisitX X
Telephone 
VisitX X X X
Laboratory Tests
Serum 
pregnancy 
testpX
Urine 
pregnancy 
testqX X X X X X X X X X
Follicle -
stimulating 
hormone 
testrX
Chemistry 
panelXs X X X X X X X X X
Fasting 
serum 
glucoseX X X X X X X X X X X X X X X
Lipid panel X X X X X X X X
I8F-MC-GPGM(b) Clinical Protocol Page 18
LY3298176Study 
Period IStudy Period II
52 WeeksStudy Period III
VariableStudy 
Period 
IV
Screening 
Lead inTreatment Period Safety 
F/U
   Visit 1 2 3a 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 FTVzETb 801
Week of 
Treatment-3 -2 0 1 2 3 4 5 6 7 8 10 12 15 16 20 23 24 28 32 35 36 42 52 62 72 78 88 1044 weeks 
post 
end of 
tx
Allowable 
Deviation 
(days)c- ±3 ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 ±3 ±3 - ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±3
Fasting Visitd X X X X X X X X X X X X X X X
PK only Visit X X
Telephone 
VisitX X X X
Urinary 
albumin/
creatinine 
ratioX X X X X X X X
Serum 
creatinine, 
eGFR (CKD -
EPI)tXs Xu X X X X X X X X X
Calcitonin Xs X X X X X X X X X
Hematology Xs X X X X X X X X X
HbA1c X X X X X X X X X X X X X X X
Pancreatic 
amylase, 
lipaseXs X X X X X X X X X
Immuno -
genicityv X X X X X X X X X X X
I8F-MC-GPGM(b) Clinical Protocol Page 19
LY3298176Study 
Period IStudy Period II
52 WeeksStudy Period III
VariableStudy 
Period 
IV
Screening 
Lead inTreatment Period Safety 
F/U
Visit 1 2 3a 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29FTV
zETb 801
Week of 
Treatment-3 -2 0 1 2 3 4 5 6 7 8 10 12 15 16 20 23 24 28 32 35 36 42 52 62 72 78 88 1044 
weeks 
post 
end of 
tx
Allowable 
Deviation 
(days)c- ±3±
7±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 ±3 ±3 - ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±3
Fasting Visitd X X X X X X X X X X X X X X X
PK only Visit X X
Telephone 
VisitX X X X
PK sample for 
Immuno -
genicitywX X X X X X X X X X
Anti-GAD 
antibodyX
LY  PKxX X X X X
   Pharmaco -
   genetic stored
   sampleX
Non-
  Pharmaco -
genetic          
stored sampleX X X X X X
I8F-MC-GPGM(b) Clinical Protocol Page 20
LY3298176Study 
Period IStudy Period II
52 WeeksStudy Period III
VariableStudy 
Period 
IV
Screening 
Lead inTreatment Period Safety 
F/U
   Visit 1 2 3a 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 FTVzETb 801
Week of 
Treatment-3 -2 0 1 2 3 4 5 6 7 8 10 12 15 16 20 23 24 28 32 35 36 42 52 62 72 78 88 1044 
weeks 
post 
end of 
tx
Allowable 
Deviation 
(days)c- ±3 ±7 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3 ±3 ±3 - ±3 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±3
Fasting 
VisitdX X X X X X X X X X X X X X X
PK only 
VisitX X
Telephone 
VisitX X X X
Patient -Reported Outcomes (PROs)y
APPADL X X X
EQ-5D-5L X X X
IW-SP X X X
DTSQs X
DTSQc X X
Abbreviations: ADA = anti -drug antibod ies; APPADL =Ability to Perform Physical Activities of Daily Living; BG = blood glucose; BP = blood pressure; 
CKD -EPI = Chronic Kidney Disease -Epidemiology; DTSQc = Diabetes Treatment Satisfaction Questionnaire change; DTSQs =Diabetes Treatment 
Satisfaction Questionnaire status; ECG = electrocardiogram; ; eGFR = estimated glomerular filtration rate; EQ-5D-5L = European Qualtiy of Life -
dimensions; ET = early t ermination; FTV = final treatment visit; F/U=follow -up; GAD = glutamic acid decarboxylase; HbA1c = hemoglobin A1c; HR = 
heart rate; IW-SP = Impact of Weight on Self Perception ;LY=LY3298176; PK = pharmacokinetics; PRO = patient -reported outcome; SGLT -2i= sodium -
glucose co -transpo rter-2inhibitor ; SMBG = self -monito red blood glucose; SU = sulfonylurea; TTT = treat-to-target ; Tx = treatment .
I8F-MC-GPGM(b) Clinical Protocol Page 21
LY3298176aBaseline assessments must be completed before processing in the interactive web -response sy stem (IWRS).
bPatients who are unable or unwilling to continue in the study for any reason will perform an ET visit. If the patient is discontinuing during an unscheduled 
visit, that visit should be performed as the ET visit. If the patient is discontinuing during a s cheduled visit, that visit should be performed as an ET visit. 
Visit 801 ( safety  follow -up v isit) should be performed 4 weeks after the ET visit as the final study visit.
cThe visit date is determined in relation to the date of the randomization visit (± the allowed visit window). 
dOn visits 3, 5, 7, 11, 13, 15, 16, 18, 2 3 , 24, 27, 29, ET ,and at follow -up (801) , patients should be reminded to report to the site in a fasting condition, after a 
period of approximately 8 hours without eating, drinking (except water), or any significant physical activity and before taking study drug(s), metformin (if 
used), SGLT -2i(if used), SU (if used) .
eMedical history includes assessment of preexisting conditions (including history of gall bladder disease, cardiovascular dise ase,and medullary thyroid 
carcinoma) and substance usage (such as, alcohol and tobacco) .
fWeight measu rements should be obtained per the detailed guidance in the Manual of Operations .
gVital sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing, at visits where 
required. The partic ipant should sit quietly for 5 minutes before vital sign measurements are taken. For each parameter, 2measurements will be taken using 
the same arm; the recordings should be taken at least 1 minute apart. BP must be taken with an automated blood pressure machine .
hDilated fund oscopic exam will be performed by a neye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to 
exclude patients with proliferative retinopathy and/or maculopathy.  The results fro m this exam will be recorded on a specific retinopathy eCRF as a baseline 
measure of retinopathy.  A follow -up dilated fundoscopic exam should be performed when clinically indicated by any adverse event suspected of worsening
retinopathy, and the findings should be recorded on the retinopathy eCRF .
iIncludes counseling on diet and exercise, management of hypoglycemia and hyperglycemia, etc .
jAll training should be repeated as needed to ensure patient compliance. 
kPatient is required to collect two 7 -point SMBGs on nonconsecutive days prior to the next visit. A 7-point SMBG consists of measurements before and 2 
hours after each of 3 main meals within the same day and at bedtime. These SMBG profiles will be collected by the patient within 2 weeks prior t o the 
assigned visits. If 7-point SMBG is not performed, then data from the most recent nonconsecutive 4-point SMBG profiles can be used. If more than 2 SMBG 
profiles are available, the 2most recent nonconsecutive profiles should be used.
lPatients sho uld administer their first dose of LY3298176 at the end of this visit, after other study procedures and randomization. 
mLY3298176 patients only.
nDuring the first 8 weeks ,the dose adjustment will be determined by the investigator in discussion with the patient by following a TTT algorithm. After 
Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at eac h office visit. Patient will 
have weekly visits (clinic or phone) in the first 8 weeks and then visits every 2 -3 weeks (clinic or phone) until Week 16 in order to improve compliance with 
the TTT algorithm .
oInsulin glargine patients only .A review of th e patient’s compliance to the TTT algorithm will still be conducted during the telephone Visits 6, 8, 9, and 12 , 
but the patient’s compliance for these visits will be collected in the eCRF at Visits 7, 10 and 13 for the period since the previous visit.
pAserum pregnancy test will be performed at Visit 1 for women of childbearing potential only.
qA urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of s tudy drug(s) for women of 
childbeari ng potential only.  Additional pregnancy tests may be performed at the investigator’s discretion during the study.  If requir ed per local regulations 
and/o r institutional guidelines, pregnancy testing can also occur at other times during the study treatmen t period.
I8F-MC-GPGM(b) Clinical Protocol Page 22
LY3298176rFollicle -stimulating hormone test performed at Visit 1 for postmenopausal women at least 50 years of age with an intact uterus, without a history of 
oophorectomy or bilateral tubal ligation, not o n hormone therapy, and who have had spontaneous ameno rrhea for more than 6 months and less than 12 
months.
sScreening visit assessment will serve as baseline .
tThe CKD -EPI equation will be used by the central lab to estimate and report eGFR. For patients whomeet inclusion criterion [4] based solely on history of 
chronic kidney disease and eGFR <60 mL/min/1.73m2, the eGFR value must be confirmed to be <60 mL /min/1.73m2at Visit 2.   
uThis sample is required only for patients whomeet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m2.
vIn the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collec ted including ADA, PK ,and,
exploratory biomarker sample.  
wPK sample for immunogenicity must be collect edprior to drug administration.
xPK s amples will not be collected from patients who were randomized to insulin glargine since it is an open -label study .  PK samples will be collected at these 
visits at time windows of 1 to 24 hours, 24 to 96 hours, OR 120 to 168 hours post dose, as assigned by IWRS. Dependent on the time -windows to which a 
patient gets assigned, they may be required to come to site for PK -specific visits. Draw PK at ET visit only if patient discontinues study prior to Week 35.
Visits 10 and 14 are for all patients, but only those patients assigned to PK will get a PK blood draw. Visits 17 and 21 are for patients assigned to a PK blood 
draw only.
yPROs should be completed before any other study procedures if the patient is not adversely affected by the fasting co nditio n or completed after the patient has 
sufficiently recovered from the preceding visit procedures.
zWhen the sponsor determines that the s tudy has met the completion criteria, all patients remaining in the study will return to the site for a 
FTV within 
approximately 30 days.   The safety follow -up visit will be approximately 30 days after the FTV.
Note: Patients will be required to collect a daily BG and a weekly 4 -point SMBG.
I8F-MC-GPGM(b) Clinical Protocol Page 23
LY32981763. Introduction
3.1. Study Rationale
Type 2 di abetes m ellitus (T2DM )is a metabo lic condi tion characterized by impaired glycemic 
control  caused by  increased insulin resistance and successive beta-cell failure and consequently 
inadequate insulin secret ion.Type 2diabetes mellitus is frequent ly associated with 
comorbidi ties such as increased weight or obesi ty, hypertensio n, and increased blood lipoprotein 
concentrations.  Patients with T2DM have a higher risk for cardi ovascular di seases (CVDs )
particularly arteriosclerotic diseases in the heart and in the central nervous system.  In case of 
prevalen t arteri oscleroti c diseases and/or chronic kidney diseases (CKD) of T2DM pati ents, the 
likelihood of a subsequent, life -threatening major cardiovascular (CV) event is very high, up to 
2% to 4%/year (Haffner et al. 1998) .  To prevent these, complex medical therapy is warranted 
beyo nd the necessary  changes in lifest yle and diet.  Among others, patients have to achieve a 
tight glycemic control by  combinati on of  various antihyperglycemic medications ( American 
Diabetes Associati on2017).  The di abetes therapy  usually starts wi th lifestyle and diet changes 
followed by 1or more oral  medicat ions.  When oral antihyperglycemic therapies are insufficient 
to reach the therapy  goal  of target glycemia, injectable therapies are added to them.  I nsulins, 
especially  basal insulins, like glargine, are basic injectable treatments after failure of the oral 
therapy .  Adequately  titrated gl argine therapy ,in combinat ion with oral treatm ent,frequent ly 
achieve sthe target glycemic level.  Glargine therap y, however, i s frequently associ ated wi th 
weight increase and eventual hypoglycemia.  LY3298176 is a 39 -amino acid synt hetic pept ide 
with agonist acti vity at both the GIP (glucose -dependent insulinotropic po lypept ide) and GLP -
1 
(glucagon -like peptide -1) re ceptors.  Its structure is based on the GIP sequence and includes a 
C20 fatty  di-acid m oiety.  It is administered once weekly (QW) by subcutaneous (SC) 
administration. The aim o f the present study  is to com pare the glycemic effect of glar gine and 
LY3298176 in patients with T2DM and elevated risk for CVD . In addit ion, the number of major 
cardi ovascular outcom e events (MACE -4) to be collected in the study  with high CV ri sk 
patients ,will largely contribute to establish ingthe cardi ovascular safet y of LY3298176 prior to 
submissio n for license, as requested by  the regul atory  agencies. The study  coul d also com pare 
the effect of these drugs on weight loss and their safet y profile.
Study  I8F-MC-GPGM (GPGM) is a Phase 3, open -label co mparator, m ulticenter, parallel -arm, 
rando mized study to compare the safet y and efficacy  of 3 maintenance doses of LY3298176 with 
insulin glargine in pat ients with T2DM with increased CVrisk.The primary endpo int will be 
the me an change hemoglobin A1c (HbA1c) fro m baseline to 52weeks.
3.2. Background
Three LY3298176 clinical trials have completed dosing and analysis:  a Phase 1 study , 
Study I8F-MC-GPGA (GPGA), and 2 Phase 2 studies, Study  I8F-MC-GPGB (GPGB) and 
I8F-MC-GPGF (GPGF).  
Phase 1 Study  GPGA was a combinat ion of single ascending do se (SAD) and mult iple ascending
dose study  in healthy subjects and a m ultiple dose study  in pat ients with T2DM.  Study GPGA 
investigated the safet y, tolerabilit y, pharm acokinetics (PK), and pharmacodynamics (PD) of 
I8F-MC-GPGM(b) Clinical Protocol Page 24
LY3298176LY3298176 administered as SC inject ions.  A total of 142 subjects (89 healthy subjects and 
53patients wi th T2DM) received at least 1 dose of tre atment.  Do ses of LY3298176 ranged from  
0.25 m g to 8 mg in the SAD ( with maximum  tolerated dose achi eved at 5 m g); m ultiple doses 
from 0.5mg to 4.5 mg QW; and titrated doses up to 10 mg QW f or 4 weeks in healthy subjects; 
and mult iples doses at 0.5 mg and 5 mg QW and t itrated to 15 mg QW for 4 weeks in T2DM 
patients.  
LY3298176 was better tol erated by  patients wi th T2DM than healt hy subjects. Doses higher 
than 5 m g were better tolerated whe n attained via escalat ion.Maximum tolerated dose of 
LY3298176 in healt hy subjects fo llowing single -dose administrati on was 5 m g. A dose of 15 mg 
LY3298176 was administered in patients with T2DM by accelerated dose escalat ionover 4 
weeks (5/5/10/15 mg) and while considered to be safe, was associated with high incidence o f GI 
events.
Gastrointestinal (GI) adverse event s (AEs) (nausea, vomit ing, diarrhea, decreased appet ite, 
abdo minal distensio n) were the m ost frequent ly reported events by both healthy subjects and 
patients wi th T2DM and were dose related.  Most AEs were mild in severit y, few were m oderate, 
and none were reported as severe.  There were no apparent trends in chemistry , hematol ogy, or 
urinalyse s.  A few subjects experienced elevat ions in lipase and/or amylase levels, but these 
episodes were not associated with drug- related risk of pancreat itis.
The safet y and tol erabilit y and PK/PD profiles of LY3298176 at doses and escalat ionregim ens 
administered in this phase 1 study  supported further development of LY3298176 for QW dosing 
in patients with T2DM.
Phase 2 studies have evaluated the efficacy, tolerabilit y, and safet y of LY3298176 in pat ients 
with T2DM wi th inadequate glycemic control on diet and exercise alone or on a stable dose of 
metformin monotherapy .
3.3. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
and reason ably ant icipated AEs of LY3298176 are to be found in the Invest igator’s Brochure 
(IB).
In addit ion, detailed informat ion about the known and expected benefits and risks of insulin 
glargine m ay be found in the insulin glargine package insert (Basaglar USPI , 2015 [WWW] ).
I8F-MC-GPGM(b) Clinical Protocol Page 25
LY32981764.Objectives and Endpoints
Table GPGM .2shows the object ives and endpo ints of the study .
Table GPGM .2. Objectives and Endpoint s
Objectives Endpoints
Primary
To demonstrate that QW LY3298176 10mg
and/o r 15mgis no ninferior to insulin glargine 
for change from baseline in HbA1c at 52
weeksMean change in HbA1c
Key Secondary (controlled for type 1 error)
Efficacy
To demonstrate that QW LY3298176 5mg is 
noninferio r to insulin glargine for change from 
baseline in HbA1c at 52 weeks Mean change in HbA1c 
To demonstrate that QW LY3298176 5mg, 
10mg,and/or 15mgis superior to insulin 
glargine for change from baseline in weight at 
52weeks
To demonstrate that QW LY3298176 5mg, 
10 mg, and/or 15mgis superior to insulin 
glargine for change from baseline in HbA1c at 
52 weeks 
To demonstrate that QW LY3298176 5mg, 
10mg,and/or 15mgis superior to insulin 
glargine for the proportion of patients with 
HbA1c target valu es of <7.0 (53 mmol/mol )at 
52 weeks .Mean change in body weight 
Mean change in HbA1c
HbA1c
Additional Secondary (not controlled for type 1 
error)
Efficacy
To demonstrate that QW LY3298176 5mg, 
10 mg, and/or 15mgis superior to insulin 
glargine at 52 weeksThe mean change in fasting serum glucose
(central laboratory) from baseline
The proportion of patients achieving an 
HbA1c target value of ≤6.5% (48 mmol/mol), 
and <5.7% (39 mmol/mol)
Mean change in 7 -point self -monitored blood 
glucose ( SMBG ) profiles from baseline
Proportio n of patients who achieved weight 
loss of ≥5%, >10%, and >15% from baseline 
Safety
I8F-MC-GPGM(b) Clinical Protocol Page 26
LY3298176To compare the safety of LY3298176 5mg, 
10mg,and 15mg LY3298176 to insulin 
glargine at 52weeks, and at the end of the 
safety follow -up period, with respect to the 
following outcomes: Treatment -emergent adverse events (TEAEs)
Early  discontinuations of study drug due to 
AEs
Adjudicated deaths and nonfatal major CV 
events
Adjudicated pancreatic AE s
Medullary  thyroid carcinoma ( MTC) and 
serum calcitonin 
Incidence of treatment -emergent (TE) 
LY3298176 anti-drug antibodies ( ADA) and 
systemic hy persensitivity  reactions
Mean change in systolic and diastolic blood 
pressure and heart rate from baseline
Occurrence of hypoglycemic events 
Incidence of initiation of rescue therapy for 
severe, persistent hyperglycemia
Pharmacokine tics
To characterize the PKof LY3298176 5mg, 
10mg,and 15mg and evaluate the 
relatio nship between LY3298176 exposure 
and safety, tolerability ,and efficacy measuresPopulation PK and PD parameters
Tertiary/Exploratory
To characterize long -term glycemic control 
with LY3298176 5 mg, 10 mg, and 15 mg
To compare LY3298176 5 mg, 10 mg, and 
15mgto insulin glargine with respect to the 
following:HbA1c
Change in lipids (total cholesterol, high -
density  lipoproteins, low-density  lipoproteins, 
very low-density  lipoproteins, and 
triglycerides) from baseline
Changes from baseline in mean body mass 
index (BMI )
Change in waist circumference
Biomarkers
Patient-Reported Outcomes (European 
Quality  of Life –dimensions [ EQ-5D-5L ], 
Ability to Perform Physical Activities of Daily 
Living [ APPADL ], Impact of Weight on Self -
Perception [ IW-SP], status (s) and change (c) 
versions of Diabetes Treatment Satisfaction 
Questionnaire (DTSQ )
I8F-MC-GPGM(b) Clinical Protocol Page 27
LY32981765. Study  Design
5.1. Overall Design
Study  GPGM i s a Phase 3, open -label co mparator, mult icenter, parallel- arm, randomized study  
to com pare the safet y and efficacy of 3 maintenance doses of LY3298176 with insulin glargine 
in patients with T2DM with increased CVrisk.  The primary  endpoint will be the mean change 
HbA1c fro m baseline to 52weeks. 
Patients shoul d be on a stabl e dose (no dose change for at least 90 day s) of at l east 1 and no m ore 
than 3 oral  antihyper glycemic medicat ions:metformin, sodium -glucose co -transporte r-2
inhibitors (SG LT-2is), or sulfo nylureas. Patients will be rando mized in a 1:1: 1:3ratio to receive 
5mg LY3298176, 10 mg LY3298176 ,15 m g LY3298176, or insulin glargine.  The 
rando mizat ion will be stratified by country , baseline HbA1c concentration ( ≤8.5%, ˃8.5% [≤69, 
˃69 mmo l/mol]), and SGLT -2i use ( YesorNo). 
The study  will continue unt il all of the fo llowing cri teria are fulfilled :
1)At least 52 we eks fro m the time of the last patient rando mized ,
2)At least 300 patients assigned to the combined LY3298176 arms reach at least 78 
weeks of treatment,
3)Approximately 110patientsin this study experience at least 1component event of the 
composite CV endpoint of cardiovascular death, my ocardial  infarct ion, stroke, or 
hospi talizati on for unstable angina .
The starting dose of insulin glargine will be 10 IU/day  at bedtime, ti trated to a fasting blood 
glucose ( FBG )<100 mg/dL, fo llowing a treat -to-target algorithm (Riddle et al. 2003).  Patients 
will t itrate the insulin glargine dose in a weekly manner and will make the dose decisio n with the 
investigator for the first 8 weeks (phone or clinic visit).  From Week 8 to Week 16 ,patients w ill
have a phone or clinic visit every  other week.
Figure GPGM .
1illustrates the study  design.   
I8F-MC-GPGM(b) Clinical Protocol Page 28
LY3298176Abbreviations:  QD = once daily; QW = once weekly; SGLT -2i = sodium -glucose 
co-transporte r-2 inhibitor; SU = sulfon ylurea.
aPatients will be on study drug f or at least 12 months and will receive no more 
than months of treatment .
bAll patients will perform a Visit 801 4 weeks after their last treatment visit.
cThe starting dose of insulin glargine will be 10 IU/day at bedtime, titrated to a 
FBG <100 mg/dL, following a TTT algorithm (Riddle et al. 2003) .
dPatients will titrate insulin glargine dose in a weekly manner and will make the 
dose decision with the investigator for the first 8 weeks (phone or  clinic 
visit). From Week 8 to Week 16 ,patients will co ntinue the titration by a phone 
consultation or clinic visit ever y other week , with 3 weeks between Visits 13 
and 14.
Figure GPGM .1. Illustration of study design for Clinical Protocol I8F-MC-GPGM .
Study Period I ( screening and lead-in)
Screening (Visit 1)
The purpose of screening procedures at Visit 1 is to establish init ial eligibilit y and to obtain 
blood sam ples for l aboratory  assessments needed to confirm eligibilit y at Vi sit 2.  Pati ents who 
meet all applicable inclusio n criteria and none of the applicable exclusio n criteria at Visi t 1 will 
continue on their prestudy  therapy  until  Visit 2.

I8F-MC-GPGM(b) Clinical Protocol Page 29
LY3298176Lead-i n (Visit 2 to Visit 3)
At Visit 2, the screening laboratory  resul ts will  be reviewed and patient eligibilit y will  be 
established.   
For th ose pati ents meet ing all other eligibilit y requirements, a dilated fund oscopi c
exam ,performed by  anophthalmo logist or optom etrist,must be completed between Visit 2 and 
Visit 3 to ensure pati ents wi th proliferat ive retinopathy or maculopathy are ident ified and not 
enrolled.  During the lead-in period, eligible patients shoul d cont inue their prestudy  therapy  (all 
oral medicati ons at the same dose), in order to allo w reliable assessment of HbA1c at baseline 
(Visit 3).  During this peri od, pati ents w ill be trained on disease monitoring and disease 
management procedures, study  diaries, and study  procedures.  
Study Period II ( 52-week treatment period)
Randomization (Visit 3)
At Visit 3, patients will perform all required baseline study  procedures (including the collect ion 
of all baseline laboratory  measures) pri or to randomizat ion and pri or to taking the first dose of 
study  drug.  Pati ents will  be randomized in a 1:1:
1:3ratio to receive 5mg LY3298176 , 10mg 
LY3298176 ,15 m g LY3298176 ,or insulin glargine.  The rando mizat ion will be stratified by 
country , baseline HbA1c concentration ( ≤8.5%, ˃8.5% [≤69, ˃69 mmo l/mol]), and SGLT -2i use 
(YesorNo).
Immediately after rando mizat ion, the pati ent will inject the first dose of LY3298176 at the study  
site, according to the dose escalat ion regimen described below.   Pati ents randomized to the 
insulin glargine arm will administer insulin glargine per the invest igators’ discretion.  The date 
and time o f the first dose of study  drug shoul d be record ed on the electroni c case report form 
(eCRF).
Following rando mizat ion, pa tients will  parti cipate in a 52 -week treatment period .  
Postrandomization period (end of Visit 3 to Visit 24)
:
The starting dose of LY3298176 will be 2.5 mg QW for 4 weeks, followed by an increase to 5 
mg QW, for the durati on of  the study  low-dose arm .  For the 10 -mg arm, the starting dose of 
LY3298176 will be 2.5 mg QW for 4 weeks, then the dose will be increased by 2.5 mg every 4 
weeks (2.5 to 5to 7.5 to 10 mg) unt il the 10 -mg dose is reached and maintained for the duration 
of the study .  For the 15 -mg arm, the starting dose of LY3298176 will be 2.5 mg QW for 4 
weeks, then the dose will be increased by 2.5 mg every 4 weeks (2.5 to 5to 7.5to 10to 12.5-15 
mg) unt il the 15 -mg dose i s reached and maintained for the duration of the study .  
The init ial dose of insulin glargine will be 10 IU/day  at bedtime, ti trated to a FBG <100 mg/dL, 
following a treat-to-
target (TTT)algorithm (Riddle et al. 2003 )(seeSection 7.2.1.2 ,Table 
GPGM. 4).
I8F-MC-GPGM(b) Clinical Protocol Page 30
LY3298176Study Period III (variable treatment period)
Long -term safety period (Visit 25to Visit 29):
Some patients will cont inue to receive LY3298176 or ins ulin glargine for up to, but not longer 
than, 24 months, as determined by the sponsor. 
When the sponsor determines that th e study  com pletion cri teria have been m et, all pat ients will 
return to the site for a final treatment visit (FTV) within approximately 30 days .  Pati ents who 
attend Vi sit 29 (24 m onths) or the FTV are considered to have co mpleted the treatment period.
Stud
y Period I V (safety follow- up period)
Safety follow -up (Visit 801) v isits:
All patients who complete the treatment period are required to complete Visit 801, a safety  
follow
-up visit approximately 4 weeks after their last visit.  Patients discont inuing the study early 
and performing an early  terminat ion (ET) visit will also be asked to perform the safet y follow-up 
visit, so that the safety  follow-up visi t will be thei r final  visit.  During the safety follow-up 
period, pati ents will not receive study  drug.  Pati ents will  be treated wi th another 
glucose -lowering intervent ion decided upon by the invest igator.  Initiation of new 
antihyperglycemic therapy for the safety follow-up p eriod will not be classified as “rescue 
therapy .”  All antihyperglycemic medicat ions will be entered on the eCRF specified for this 
purpose.  Patients are also required to return any  remaining study  diaries to the study  site at the 
end of this period.
Study Procedures
Patients will  perform study  procedures liste d in the Schedule of Activit ies (Secti on2).  
Patients will  be permitted to use concomitant medications that they  requi re during the study , 
except certain medicat ions that may interfere with the assessment of efficacy and safet y 
characterist ics of the study  treatm ents.  Prohibited medicat ions include GLP -1 receptor agoni sts,
amylin analogs, and dipept idyl pept idase -
4 (DPP-4)inhibitors (see Section 7.7).  
Pharmacokinet ic samples will be co llected from the first 150 patients at each LY3298176 dose, 
all patients age d≥70 y ears, and all pat ientswith severe renal impairment or end -stage renal 
disease (ESRD) (estimated glo merular filtrat ion rate [ eGFR
]<30 m L/min) (see Sect ion 9.5).
Patients who develop severe, persistent hy perglycemia based on prespecified thresho lds (see 
Secti ons7.2.1.2 and 9.2.2.2 ) will receive a new glucose -lowering intervent ion (“rescue therapy”) 
and will also continue to administer study  drug.  Pati ents who need hyperglycemic rescue 
therapy  will cont inue in the trial unt il they co mplete all study  visits.  
Study  governance considerations are described in detail in Appendix 3 .
I8F-MC-GPGM(b) Clinical Protocol Page 31
LY32981765.2. Number of Participants
A total o f approximately  1878 patients will be randomized in a 1:1:1:3 ratio to 5mg LY3298176
(313 patients), 10mg LY3298176 (313 patients), 15 mg LY3298176 (313 patients), and insulin 
glargine (93 9patients) .
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2)for the last patient.
5.4. Scientific Rationale for Study Design
Study  GPGM is designed to determine the co mparative benef its and ri sks of QW LY3298176
5mg,10 m g, or 15 mg versus insulin glargine in patients with T2D Mwith increased CVrisk. 
An act ive co mparator rather than placebo was selected for this trial because it includes patients 
with uncontrolled T2DM despite of oral antihyperglycemic therapies (7.5% [58 mmo l/mol]to 
10.5% [91 mmo l/mol],inclusive) and increas ed risk for CVD s who will be studied for a longer 
period,up to 2 years .  To ensure a valid comparison of the rando mized study treatments, it is 
important that insulin glargine is titrated optimally throughout the entire study .  Patients will be 
requi red to use a TTT algorithm, which has been shown to be effective in enabling a high 
proporti on of  patients with T2D Mto achieve their therapeutic targets when treated with insulin 
glargine (Ri ddle et al. 2003) as described in Sect ion 7.2.1.2 .
To minimize the potential confounding effect of changes to concomitant medications, patients 
will be permitted to use concomitant medicat ions that they  require during the study . Medi cations 
that may  interfere wi th the assessment of efficacy and safet y characteri stics of the study  
treatm ents will not be allowed (see Section7.7).  
The pl anned durat ion of treat ment for the primary endpoint at 52weeks is considered appropriate 
to assess the full effects and benefit/risk of each maintenance dose of LY3298176 compared with 
the other LY3298176 doseson both glycemic control and body  weight.  The variable treatment 
durati on of  up to, but not longer than 104 weeks ,will provide sufficient 18- month pat ient 
exposures to meet regulatory  requi rements and to provi de sufficient numbers of patients with a 
major adverse CV event (MACE -4:  CV death, myocardial infarct ion, stro ke, or hospitalization 
for unstable angina) for the meta -analysis to rule out excess CV risk.
5.5. Justification for Dose
LY3298176 doses of 5 mg, 10 mg ,and 15 m g administered subcutaneously  QW will  be 
evaluated in this study . 
These doses and associated escal ationschemes were sel ected based on assessment of safet y, 
efficacy  (glycemic and weight l oss benefit), and GI to lerabilit y data fo llowed by  exposure 
response modeling of data in T2DM patients in Phase 1 and 2 studies. Dosing algorithms 
starting at a lowdose of 2.5 m g accompanied by dose escalat ion of 2.5 m g increments every 
4-week would permit time for development of tolerance to GI events and are predicted to 
minimize GI tolerabilit y concerns.
I8F-MC-GPGM(b) Clinical Protocol Page 32
LY3298176The m aximum  proposed dose of 15 m g maintains an exposure mul tiple o f 1.6to 2.4 to the 
no-observed adverse effect level doses in 6-month monkey and rat toxico logy studi es.
The selected dose and escalation scheme woul d enable further evaluat ion of benefit/risk 
considerations for 5mg, 10mg,and 15 mgdoses of LY3298176 .
I8F-MC-GPGM(b) Clinical Protocol Page 33
LY32981766.Study  Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if th ey meet all  of the f ollowing criteria at 
screening:
Type of Patient and Disease Characteristics
[1] Have been diagnosed with T2DM based on the W orld Health Organizat ion
classificat ion or other locally  applicable diagnostic standards
Patient Characteristics
[2] Have HbA1c between ≥7.5%(58 mmo l/mol)and ≤10.5% (91 mmo l/mol)at 
screening as determined by  the central  laboratory  at Visit 1
[3]On stable treatment with unchanged dose of at least 1 and no m ore than 3 oral  
antihyperglycemic drugs, which may only  include met formin, SGLT -2i, 
and/or sulfonylurea for at least 3 months before Visit 1
[
4]Increased ri sk of CVevents as defined by at least 1 of the f ollowing (a –e):
a)Coronary  heart di sease docum ented as having any of the fo llowing:
1)History  of acute my ocardial  infarct ion (ST elevation or non-ST 
elevation) 
2)Stenosis of ≥50% in at l east 1 major (left main, left  anterior 
de
scending, ram us interm edius, left ci rcumflex, ri ght) coronary  artery  
as determined by  cardiac imaging
3)Coronary  calci um score ≥300
4)Stabl e angina pectoris treated wi th anti-anginal  medication
5)Asymptomat ic cardiac ischemia documented by cardiac imaging on 
exercise or pharmaco logical stress test
6)History  of coronary  revascularizat ion (percutaneous coronary  
intervent ion or co ronary  artery  bypass surgery )
OR
b)Peripheral  arterial  disease presumed to be of atherosclerotic origin 
docum ented as a history  of any of the fo llowing:
1)Current or intermittent claudication
2)Resting limb ischemia
3)Stenosis of >50% in an iliac, femoral, poplite al, or subclavian artery
4)An ankle -brachial index ≤0.90
5)Peripheral  arterial  revasculari zation or am putati on due to 
atherosclerotic vascular disease
6)Asymptomat ic carotid artery  stenosis ≥70%
7)Caroti d artery  revascularizat ion
I8F-MC-GPGM(b) Clinical Protocol Page 34
LY32981768)Abdo minal aortic aneurysm
OR
c)Cerebrovascular disease presumed to be of atherosclerotic origin 
docum ented as a history  of ischemic stroke or transient ischemic attack 
(TIA).  Patients with a history  of TIA m ust be age ≥50 y ears.
NOTE:  Does not include stroke or TIA due to nonatherosc lerotic causes, 
for example, hypertensio n, embo lism, or hem orrhagi c stroke
OR
d)Age ≥50 years, h istory  of CKD ,and an est imated glo merular filtrat ion rate 
<60mL/min/1.73m2(CKD -Epidemi ology[CKD -EPI]) on consecut ive 
measurements (Visit 1 and Visit 2) 
OR
e)Age ≥50 years and c ongest ive heart failure (CHF) documented as a history  
of CHF by  the New York Heart Associat ion Funct ional Classification II to
III
[5] Are of stable weight (± 5%) ≥3 months prior to Visit 1 and agree to not init iate an 
intensive diet and/or exercise program during the study  with the intent of reducing 
body  weight other than the lifest yle and dietary measures for diabetes treatment 
[
6] Have a BMI ≥25 kg/m2at Vi sit 1
[
7] Eighteen years or ol der at the time of signing informed consent
Male patients:
Male patients should be willing to use reliable contraceptive methods throughout 
the study  and f or at least 3 m onths after l ast inject ion 
Female pat ients:
Female pat ients not of childbearing potential due to surgical sterilizat ion 
(hysterectomy , bilateral  oophorectomy ,or tubal  ligation) or m enopause.
Women with an intact uterus are deemed postmenopausal if they are 45 y ears 
old, and
have no t taken hormones or oral contraceptives within the last y ear 
and had cessat ion of menses for at least 1 y ear
OR
have had at least 6 months of amenorrhea with fo llicle -stimulat ing 
horm one (FSH) and estradio l levels consistent with a 
postm enopausal state (FS H ≥40 mIU/mL and estradio l 
<30pg/mL).
Female pat ients of child bearing potential (not surgically sterilized and 
between m enarche and 1 -year postm enopausal ) must
I8F-MC-GPGM(b) Clinical Protocol Page 35
LY3298176test negative for pregnancy  at Vi sit 1 based on a serum  pregnancy 
test
AND
if sexually  active, agree to use 2forms of effect ive contraception, 
where at least 1form is highly effect ive for the durati on of  the tri al 
and for 30 days thereafter 
not be breastfeeding
[8] In the invest igator’s opinio n, are well mot ivated, capable, and willing to
performSMBG (up to 7 m easures in a day )
learn how to self
-inject treatm ent (LY3298176 or insulin glargine), as 
requi red for thi s protocol  (visually  impaired persons who are not able to 
perform  the inject ions must have the assistance of a sighted individual 
trained to inject the study  drug; persons wit h physical limitat ions who are 
not able to perform the inject ions must have the assistance of an individual 
trained to inject the study  drug) 
are willing and able to inject study  drug QW/once daily  
maintain a study diary , as requi red for this protocol
have a sufficient understanding of one of the provided language sof 
the country  such that they  will be able to com plete the pati ent 
questionnaires
Informed Consent
[9] Have given written informed consent to participat e in this study  in accordance 
with local regulat ions and the Ethical R eview Board (ERB) governing the 
study  site 
6.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet anyof the fo llowing cri teria at
screening :
Medical Conditions
[10]Have t ype 1 diabetes mellitus (T1D M )
[11]Had chronic or acute pancreatit is any t ime prior to study entry (Visit 1)
[12]Have a history  of proliferat ive diabet ic retinopathy or diabet ic maculopathy (a 
dilated fundoscopic exam ,performed by a nophthalm ologist or optom etrist
between Visit 2 and Visit 3,is required to confirm eligibilit y )or 
nonpro liferat ive diabet ic retinopathy that requires acute treatment
[13]Have a history  ofketoaci dosis or hy perosm olar state/com a 
[14] Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode 
of hypoglycemia unawareness wit hin the 6 m onths pri or to Vi sit 1
I8F-MC-GPGM(b) Clinical Protocol Page 36
LY3298176[15]Have a known clinically significant gastric empt ying abnormalit y (for 
example, severe diabet ic gastroparesis or gastric outlet obstructi on), have 
undergone gastric bypass (bariatric) surgery  or restri ctive bariatric surgery 
(for example , Lap -Band®), or chronically  take drugs that di rectly affect GI 
motility
[16] New York Heart Associat ion Funct ional Classification IV congestive heart failure
[17]Have any of the fo llowing CV condit ions wi thin 2 m onths prior to Vi sit 1:
acute my ocardial  infarct ion, cerebrovascular accident (stro ke), or 
hospi talizati on for CHF
[18]Have acute or chronic hepat itis, signs or symptoms of any other li ver disease, 
or an al anine aminotransferase (ALT) level >3.0 the upper limit of normal 
(ULN) for the reference range, as determined by the central laboratory .  
Patients wi th nonalcoho lic fatty liver di sease are eligible to participate only if 
their ALT level is ≤3.0 the ULN for the reference range
[19]Have evidence of a significant, uncontrolled endocrine abnormalit y (for 
example, th yrotoxi cosis or adrenal crises), in the opinio n of the investigator
[
20] Have family or personal history  of medullary thy roid carcino ma or Multiple 
Endocrine Neoplasia syndrome t ype 2
[21]
Have a serum calcitonin level of
(a) ≥20 ng/L at Visit 1, if eGFR ≥60 m L/min/1.73m2
(b)≥35 ng/L at Visit 1, if eGFR <60 mL /min/1.73m2
[22]Have evidence of significant, active autoimmune abnorm ality (for example , 
lupus, rheumatoid arthrit is) that, in the opinio n of the invest igator, is likely to 
requi re concurrent treatment with systemic glucocorticoids in the next 12 
months.
[23]Known or suspected hypersensit ivity to trial product(s) or related products
[
24] History  of hypersensi tivity to insulin glargine
[25] Have had a transplanted organ (corneal transplants [keratoplasty ] allowed) or 
awaiting an organ transplant
[26] Have a history  of an act ive or untreated malignancy or are in remiss ion from a 
clinically significant malignancy (other than basal or squamous cell skin 
cancer, in situ carcino mas of the cervix, or in situ prostat e cancer) for less than 
5 years
[
27]Have a history  of any other condit ion (such as known drug, alcoho l abuse ,or 
psychiatric disorder) that, in the opinion o f the investigator, may preclude the 
patient from following and co mpleting the protocol
[28] Have any hematological condit ion that m ay interfere with HbA1c 
measurement (for example, hemo lytic anemias, sickl ecell disease)
I8F-MC-GPGM(b) Clinical Protocol Page 37
LY3298176Prior/Concomitant Therapy
[29] Have a history  of insulin therapy except for the use of insulin for treatment of 
gestati onal diabetes or acute , tem porary use of  insulin (≤14 days) , for 
example, for acute illness, ho spitalizat ion, elective surg ery
[
30] Treatment with any glucose -lowering agent(s) other than stated in the 
inclusio n criteria (incl uding DPP -4 inhibitors and GLP -1 receptor agonists) in 
a period of 3 months before screening prior to Vi sit 1   
[
31] Are receiving chronic (>2 weeks or 14 day s) systemic glucocortico id therapy 
(excluding topical, intra -ocular, intranasal, or inhaled preparations) or have 
received such th erapy  within 1 m onth of Visit 1
[
32]Have been treated with drugs that promote weight loss ( for example , Saxenda 
[liraglutide 3.0 mg], Xenical®[orlistat], Meridia®[sibutramine], Acutrim®
[phenylpropanolamine], Sanorex®[mazindo l], Apidex®[phentermine], 
BELVIQ®[lorcaserin], Qsymia™[phentermine/topiramate combinat ion], 
Contrave®[naltrexone/bupropion] ,or similar other body  weight l oss 
medicat ions including over -the-counter [OTC] medicat ions [for example , 
allī®]) wi thin 3 monthsprior to Vi sit 1and/or between study  entry  (Visi t 1) 
and randomization (Visit 3)
Prior/Concurrent Clinical Trial Experience
[33] Are current ly enrolled in any other clinical study  involving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study
[
34] Have participated, within the last 30 day s, in a clinical study  involving an 
investigat ional product.  If the previous investigational product has a long 
half-life, 5 half -lives or 30 day s(whichever i s longer) shoul d have passed
[
35] H ave previously co mpleted or withdrawn fro m this study  or any  other study  
investigat ing LY3298176
Other Exclusions
[
36] A re invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a sp ouse, parent, child, or 
sibling, whether bio logical or legally adopted
[
37] A re Lilly  empl oyees 
[
38] A re unwilling or unable to comply  with completing a diary to record data 
from the subject
6.3. Lifestyle Restrictions
Per the Schedule of Act ivities (Section 2), qualified medical staff will provide diabetes 
management counseling, which will include instructions on diet and exercise and educat ion 
about the signs, symptom s, and treatm ent of hypoglycemia , 
shoul d it occur .  
I8F-MC-GPGM(b) Clinical Protocol Page 38
LY3298176Patients shoul d cont inue their usual exercise habits and generally fo llow a heal thy meal plan 
(with consistent meal size and time of day ) throughout the course of the study .  Dietary  
couns eling m ay be reviewed throughout the study , as needed.   Per inclusio n criterion [5] (Secti on 
6.1), patients should not init iate during the study  an organi zed di et and/or exercise weight 
reducti on program other than the lifestyle and dietary  measures for di abetes treatm ent.
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study .
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study (screen failure ) mustnot 
be rescreened .  
I8F-MC-GPGM(b) Clinical Protocol Page 39
LY32981767.Treatment s
7.1. Treatments Administered
Patients will  be randomized in a 1:1:1:3 ratio to receive LY3298176 5 mg, LY3298176 10 m g, 
LY3298176 15 m g, or insulin glargine.  LY3298176 will be administered QW asSCinject ion in 
patients wi th T2D who are al ready  treated wi th a stable dose of at least 1 and no more than 3 oral 
antihyperglycemic medicat ions:metformin, sodium -glucose co -transporter -2inhibitors, or 
sulfo nylureas.  
Table GPGM. 3shows the rando mized treatm ents for the ent ire treatm ent peri od.
The starting dose of LY3298176 will be 2.5 m g QW for 4 weeks, followed by an increase to 5 
mg QW, for the durati on of  the study  low-dose arm.  For the 10 -mg arm, the starting dose of 
trizepat ide will be 2.5 mg QW for 4 weeks, then the dose will be increased by 2.5 mg every 4 
weeks (2.5 to 5to 7.5 to 10 mg) unt il the 10 -mg dose is reached and maintained for the duration 
of the study .  For the 15 -mg arm, the starting dose of LY3298176 will be 2.5 mg QW for 4 
weeks, then the dose will be increased by 2.5 mg every 4 weeks (2.5 to 5to 7.5to 10to 12.5 to 
15 m g) until the 15 -mg dose is reached and maintained for the duration of the study.  
The starting dose of insulin glargine will be 10 IU/day  at bedtime, ti trated to a FBG <100 mg/dL, 
following a treat -to-target algorithm (Riddle et al. 2003).  Pa tients will  titrate the insulin glargine 
dose in a weekly  manner and will make the dose decisio n with the investi gator f or the first 
8weeks (phone or clinic visit).  For further dose titration, f rom Week 8 to Week 16 ,patients will 
have a phone or clinic visit every  other week.
Table GPGM. 3
. LY3298176 Treatment Regimens
Treatment 
GroupTreatment Period Interval
Weeks
0to3Weeks
4to7Weeks
8to11Weeks
12 to 15Weeks
16 to 19Weeks
20 to104
15 mg 
LY32981762.5 mg 5 mg 7.5 mg 10 mg 12.5 mg 15 mg
10 mg 
LY32981762.5 mg 5 mg 7.5 mg 10 mg
5 mg 
LY32981762.5 mg 5 mg
Note:  All doses will be administered QW using asingle -dose prefilled syringe .
The invest igator or hisor her designee is responsible for the following:
explainin g the correct use of the investigational agent(s) to the patient
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection
as well as records of interruptions in study  drug a dministrati on
I8F-MC-GPGM(b) Clinical Protocol Page 40
LY3298176patient shoul d be instructed to discard all used syringes for LY3298176 or pens 
for insulin glargine in a closeable, puncture -resistant con tainer and dispose 
according to local regulations
7.1.1. Packaging and Labeling
The sponsor will provide LY3298176 in prefilled syringes and ins ulin glargine in prefilled pens.  
These will be dispensed via an interactive w eb-response system  (IWRS).  Prefilled syringes and 
prefilled pens will be packaged in cartons to be dispensed.  Clinical trial materials wi ll be labeled 
according to the country’s regulatory  requi rements.  
7.1.2. Medical Devices 
The combinat ion products provided fo r use in the study  are LY3298176 investigat ional prefilled 
syringe and a m arketed insulin glargine prefilled pen.
7.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized to 1 of the study  treatm ent arm s 
at Vi sit 3.  Assignment to treatment arms will be determined by a computer -generated random 
sequence using an IWRS.  Patients will be rando mized in a 1:1:1:3 ratio to receive 5mg 
LY3298176 , 10mg LY3298176 ,15 m g LY3298176 ,or insulin glargine.  The randomizat ion 
will be stratified by country , baseline HbA1c concentration ( ≤8.5%, ˃8.5% [≤69, ˃69 
mmo l/mol]), and baseline SGLT -2i use ( YesorNo). 
7.2.1. Selection and Timing of Doses
7.2.1.1.
LY3298176
Assignment to LY3298176 (3 doses) or insulin glargine will occur at randomization.  
There are no restrict ions on the time of day  each weekly dose of LY3298176 is given, but it is 
advisable to administer the SCinjecti ons on the same day  and same time each week.  The actual 
date and time of all dose administrations will be recorded by the patient .  If a dose of 
LY3298176 is missed, the patient should take it as soon as possible unless it is within 72hours 
of the next dose, in which case ,that dose should be skipped and the next dose should be taken at 
the appropriate time.  
7.2.1.2. Insulin Glargine
Dosing for patients randomized to insulin glargine will start at 10 units once daily. Patients 
shoul d administer thei r daily do ses at the time of day  agreed upon between the patient and the 
investigator, ty pically  before bedt ime.  Patients assigned to the insulin glargine treatment arm 
will be instructed to adjust insulin glargine doses to a target FBG of <100 mg/dL (5.6 mmo l/L) 
based on the median value of the last 3 self -monitored fasting blood glucose ( SMBG ) values 
according to the schedule below ( Riddle et al . 2003 ).  Insulin glargine dose adjust ments shoul d 
occur once in a week .After Week8, pati ents will continue to adjust insulin glargine per the 
titration algori thm; the insulin glargine dose will be also reviewed and revised, as needed, at 
subsequent office visits. There will be no central oversight of insulin glargine titration. Add-
on 
I8F-MC-GPGM(b) Clinical Protocol Page 41
LY3298176glycemic rescue therapy  should be initiated for patients who met prespecified criteria for severe, 
persistent hy perglycemia ,and further titration of glargine cannot control the condit ion (see Table 
GPGM. 4).
Table GPGM. 4
. Titration of Insulin Glargine
Median Fasting Blood Glucosea
Adjustment of Insulin Glargine mg/dL mmol/L
≤70 ≤3.9 Decrease by 2 to 4 unitsb,c
71 to99 4.0 to5.5 No adjustment
100 to119 5.6 to6.6 Increase by  2 units
120 to139 6.7 to7.7 Increase by  4 units
140 to179 7.8 to9.9 Increase by  6 units
≥180 ≥10.0 Increase by  8 units
Abbreviation:  SMBG = self-monitored blood glucose.
aBased on the last 3 self -monitored fasting blood glucose ( SMBG ) values .
bDose should also be decreased by 2 to 4 units in the following situations:
If multiple episodes of nonsevere hypoglycemia were recorded during the assessment period at any time 
during the day; and/or
If at least 1 episode that met the criteria for severe hypoglycemia (events requiring assistance to administer 
therapy ) or was associated with self -monitored blood glucose (SM BG) value <54 mg/dL (<3.0 mmol/L) 
was recorded during the assessment period.
cIf only 1 hypog lycemic episode wi th SM BG value ≥54 mg/dL (≥3.0 mmol/L) and ≤70 mg/dL (≤3.9 mmol/L) was 
recorded, insulin dose should not be changed.
Source:  Riddle et al .2003.
7.3. Blinding
This tri al is open -label due to the difference sin dosing schedule , titration, and devices between 
QW LY3298176 and once -daily  insulin glargine.
7.4. Dosage Modification
7.4.1. Study Drugs
Details about dose administration of LY3298176 during the stud y are described in Sections 7.2.1
and 8.1.2 .
Insulin glargine will be adjusted according to the TTT method (see Section 7.2.1.2 ,
Table GPGM. 4).
7.4.2. Reduction and/or Discontinuation of Concomitant 
Antihyperglycemic Medications
Temporary  discont inuat ion of conco mitant antihyperglycemic medicat ions <14 consecut ive days 
is allowed for certain clinic al situations (for example, severe dehydrat ion, elective surgery, or 
need for radio logic exam invo lving IV iodinated contrast dy e).
In the event of a hypoglycemic episode(s) (clinical symptoms of hypoglycemia and /or bl ood 
glucose (BG)-confirmed symptomat ic BGhypoglycemia [glucose concentrati on ≤3.
1mmo l/L 
I8F-MC-GPGM(b) Clinical Protocol Page 42
LY3298176[{56 mg/dL }]), in pati ents on any  oral treatm ent combinat ion containing sulfo nylurea, the 
sulfo nylurea dosage shoul d be reduced or discontinued. In pati ents not on sulfo nylurea 
(anymore) but on dual  oral treatm ent of  metformin and SGLT -2i, in case of (further) 
hypoglycemic episode(s), the dose of met formin shoul d be reduced or discont inued prior to 
reducing/discont inuing SGLT -2i. When hypoglycemia develops in pat ients on any  oral 
monotherapi es, the dose of this oral medicat ion should be reduced or di scont inued. For further 
inform ation see Sect ion9.2.2.1 .
7.5. Preparation/Handling /Storage/Accountability
The invest igator or his or her designee is responsible for the following:
confirming appropriate temperature condit ions have been maintained during 
transi t for all study  treatm ent received and any discrepancies are reported and 
resolved before use of the study  treatm ent.
ensuring that only participants enro lled in the study may receive study treatment 
and only  authori zed si te staff may  supply  or administer study  treatm ent. All study 
treatm ents m ust be stored in a secure, environmentally  controlled, and m onitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions 
with access limited to the invest igator and authorized site staff .
the invest igator, inst itution, or the head of the medical inst itution (where 
applicable) is responsible for study  treatm ent accountabilit y, reconciliat ion, and 
record m aintenance (such as receipt, reconciliat ion,and final disposi tion records ).
The study  site must store the study  drug in a l ocked and secure environment. Please ref er to the 
study  drug l abel fo r specific storage condit ions. Patients will receive insulated bags with cooling 
gel packs for use in transporting the study  drug carton from  the si te to hom e. 
Study  site staff must regul arly assess whether the patient is cor rectly administering the assigned 
study  drug and storing the study  drug according to the provided instructions. 
7.6. Treatment Compliance
Study  drug com pliance will  be determined by  the foll owing:
Study  drug administration data will be recorded by the patientand reviewed by 
the invest igator at each study visit.
T
he pati ents will  be instructed to return any  unused study drug and/orempt y 
cartons at the next visit to the study  sitefor the purpose of performing drug 
accountabilit y.
In the 3LY3298176 treatm ent arms, as well as the insulin glargine arm, treatment compliance 
for each visit interval is defined as taking at least 75% of the required doses of study  drug. 
Similarly, a patient will be considered significant ly nonco mpliant if he or she is judged by the 
investigator to have intent ionally or repeatedly taken more than the prescribed amount of 
medicat ion.  
I8F-MC-GPGM(b) Clinical Protocol Page 43
LY3298176In addit ion to the assessment of a patient’s co mpliance with the study drug administration, other 
aspects of compliance wit h the study  treat ments will be assessed at each visit based on the 
patient’s adherence to the visit schedule, compliance with the concomitant antihyperglycemic 
medicat ion regimen, complet ion of study  diaries, the resul ts of home BG m onitoring, and any 
other parameter s the invest igator considers necessary .
Initially, patients considered to be poorly  com pliant wi th their medicat ion and/or the study  
procedures will receive addit ional training and instruction, as required, and will be reminded of 
the importance of complying wit h the protocol. 
7.7. Concomitant Therapy
Patients will  be permitted to use concomitant medications that they  requi re during the study , 
except certain medicat ions that may interfere with the assessment of efficacy and safet y 
characterist ics of the study  treatm ents.  Prohibited medicat ions include GLP -1 receptor agoni sts, 
amylin agonists, and DPP -4 inhibitors.  The list of excluded medicat ions and procedures is 
provi ded in the Manual o f Operati ons.  Ot her m edicati ons f or glycemic control for patients 
meet ing severe persistent hyperglycemia criteria for rescue may be added during the study  at the 
investigator’s discret ion.Patients on the insulin glargine arm  shoul d receive other 
antihyperglycemic medicat ion only when further dose adjustment of glargine cannot control the 
persistent hy perglycemia .
Short -term insulin use is allowed for certain clinical situat ions (for example, elect ive surgery, 
during hospi talizati on, hyperosm olar states).  Rescue therapy  with other glucose -lowering agents, 
including basal or ra pid act inginsulin s, may be m edically indicated in certain situations after 
rando mizat ion due to severe, persistent hy perglycemia or early  discontinuat ion of study  
treatm ent. If insulin is prescribed as a rescue therapy, it must be different iated fro m short-term 
use of insulin therapy  for m edical emergencies when reported in the eCRF.
Invest igative site staff will inform pat ients that they must consult with the investigator or a 
designated site staff member upon being prescribed any new medicat ions during the study .  Thi s 
may not be possible when init iated for treatment of medical emergencies, in which case ,the 
patient will inform the invest igator or a designated site staff member as soon as possible.  Any 
additional medicat ion initiated during the course of the study  (including OTC drugs, such as 
paracetamo l or aspi rin) must be docum ented, and the name of the drug and the date (s)of 
administration must be recorded on the “Conco mitant Medicat ions” sect ion of the eCRF. 
All nonstudy  medicati ons will be reco rded on the eCRF at all  visits.
Nonst udy medicat ions taken by  patients who are screened but not randomized will not be 
reported to Lilly  unless an SAE or AE occurs that the invest igator believes may have been 
caused by  a study  procedure.
7.7.1. Management of Pati ents with Gastrointestinal Symptoms
In the Phase 2 program, the most commo nly reported treatment -emergent adverse events 
(TEAEs) for pati ents receiving LY3298176 were nausea, vo miting, and diarrhea.  
I8F-MC-GPGM(b) Clinical Protocol Page 44
LY3298176The LY3298176 dose escalation scheme has been designed to minimize the development of 
intolerable GI symptom s.  The escalat ion peri od is considered to be 24 weeks, which allows 20 
weeks to escalate to 15 mg and addit ional 4 weeks to reach steady  state.  During the dose 
escalat ion peri od, every  effort shoul d be made by the invest igator to be able to escalate and 
maintain patients on the corresponding study  drug dosage. 
To mit igate GI symptoms and manage patients with intolerable GI AEs, the invest igator shoul d:
Advisepatients to eat sm aller m eals, for example, splitt ing 3 daily meals into 4 or more 
smaller meals, and to stop eating when they  feel full.
Prescrib esymptom atic 
medication (f or example, ant i-emetic or anti -diarrheal  medicat ion) 
per local country  availabilit y and individual patient needs. Use of symptom atic 
medicat ion shoul d be captured as concomitant medicat ion in the eCRF .
Temporarily  interrupt LY3298176 ( omit 1 dose , the pati ent will take 3 of 4 doses at that 
dose l evel).  The data rel ated to tem porary  interruption of study  treatm ent shoul d be 
docum ented in source documents and entered on the eCRF.
After the interruption, restart at the same dose with the patient taking medicat ion to 
alleviate their GI symptoms (Section 8.1.2 ).
If intolerable GI symptoms or events persist despite the above measures, the invest igator may 
decide to con tinue treatm ent at a l ower, tol erated maintenance dose of LY3298176 (5 mg or 
10mg).  
Patients at 5 mg or l ower will be discont inued from LY3298176.
Patients at 7.5 mg or 10 mg will decrease the dose to 5 mg.
Patients at 12.5 mg or 15 mg will decrease the dose to 10 mg.
If de- escalat ion of the LY3298176 dose is necessary, the invest igator will use the IWRS to 
receive the appropriate LY3298176 dispensing information.  If de -escalati on is needed between 
scheduled visits, the IWRS will have unscheduled visit s (for example, Visit 13a) dedicated to 
provi de dispensing informat ion for pati ents whose dose has been de -escalated. Those patients 
who have their dose de -escalated, will not be escalated again. The dose can be de -escalated only  
once.  After that, the patients will have to discont inue LY3298176 if intolerable GI AE persists.  
Please see the Manual o f Operati ons for more detailed instructions.
If intolerable persistent GI symptoms occur after 24 weeks, the investigator should take the 
above measures to keep the patient on study  treatment.  However, after the escalation period 
(Week 24), dose decreases will not b e permitted.
7.8. Treatment after the End of the Study
7.8.1. Treatment after Study Completion
LY3298176 will not be made available after conclusion of the study  to pati ents.
I8F-MC-GPGM(b) Clinical Protocol Page 45
LY32981767.8.2. Special Treatment Considerations
Invest igators will be trained on how to apply decisio n criteria for the timing and method of 
intervent ion in patients who do not reach glycemic targets during the treatment period.  An 
additional therapeuti c intervent ion should be considered forpatients with persistent 
hyperglycemia as described in Sect ion 9.2.2.2 .
I8F-MC-GPGM(b) Clinical Protocol Page 46
LY32981768.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
8.1.1. Permanent Discontinuation from Study Treatment
Possible r easons leading to permanent discontinuatio n of invest igational product :
Patient Decision
oThepatientrequests to discont inue invest igational product.
Discontinuation due to a hepatic event or liver test abnormality .  Patients who are 
discontinued fro m invest igational product due to a hepat ic event or liver test abnormalit y 
shoul d have addi tional hepatic safet y data collected via the electroni c case report form 
(eCRF) .
Discontinuati on of  the invest igational product for abnorm al liver tests should be
considered by the investigator when a patient m eets one of the fo llowing condi tions af ter 
consultation wit h the Lilly designated medical monitor:
oALT or aspartate aminotransferase (AST) >8X ULN
oALT or AST >5X ULN for more than 2 weeks
oALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN or 
internat ional norm alized rati o (INR)>1.5
oALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, an d/or eosinophilia (>5%)
oalkaline phosphatase (ALP) >3X ULN
oALP >2.5X ULN and TBL >2X ULN
oALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
In addit ion, pati ents will  bediscont inued fro m the investigat ional product in the 
following circumstances:
oIf a patient is inadvertent ly enro lled and it is determined that continued treatment with 
study  drug woul d not be medically  appropriate (see Secti on 8.1.3 )
oAcute or chronic p ancreat itis 
oIf a patient is diagnosed with MTC after randomization
oIf a patient is diagnosed with an active or untreated malignancy (other than basal or 
squamous cell skin cancer, in situ carcino mas of the cervix, or in situ prostate cancer) 
after randomizat ion
oAny significant study  drug -related hypersensit ivity reacti on
oAny other TEAE, SAE, or clinically significant laboratory  value for which the 
investigator believes that permanent study  drug di scontinuat ion is the appropriate 
measure to be taken
I8F-MC-GPGM(b) Clinical Protocol Page 47
LY3298176oIffemale patient beco mespregnan t
oIf a patient is diagnosed with T1DM
Patients who stop the study  drug permanent ly may receive another glucose -lowering inte rvent ion
(Secti on 7.4.2 ) and will cont inue participating in the trial according to the protocol to collect all
planned efficacy  and safet y measurem ents.
Patients di scont inuing fro m the invest igational product prematurely for any reason should 
complete AEand other fo llow-up procedures per Section 2(Schedule of Act ivities), Section 9.2
(Adverse Events) ,and Section 9.4(Safet y) of this protocol .
8.1.2. Temporary Interruption of Study Treatment 
In certain situat ions after rando mizat ion, the investigator may need to temporarily inter rupt study  
drug. Every effort should be made by the invest igator to m aintain pat ients on study  drug and to 
restart study  drug after any  temporary  interruption, as soon as it is safe to do so.
If the number of doses missed is ≤2, the treatment can be restarted at the same dose, if the 
drug was well tolerated prior to discont inuat ion.
If the number of missed doses is ≥3, then the treatment should be restarted at 5 mg 
irrespect ive of the dose the patient was receiving before the interruption and 
subseque ntly,escalated as required by protocol (See Manual o f Operati ons for further 
details) .
If study  drug interrupti on is due to an AE, the event is to be documented and fo llowed according 
to the procedures in Section 9.2of this protocol.  If the study  drug interrupti on is due to 
intolerable persistent GIAE ( for example, nausea, vo miting, or diarrhea ), the pati ents shoul d be 
treated as suggested in Sec tion 7.7.1 .  
The data related to temporary  interrupti on of  study treatm ent will  be entered on theeCRF.
8.1.3. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ifiesa pati entwho did not meet enrollment criteria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm ent unless there 
are extenuat ing circumstances that make it medically necessary  for the pati ent to conti nue on 
study  treatm ent.  If the invest igator and the sponsor clinical research physician (CRP )agree that
it is medically appropriate to continue, the invest igator m ust obtain documented approval from 
the sponsor CRP to a llow the inadvertent ly enrolled patientto con tinue in the study  with or 
without treatm ent wi th invest igational product. Safet y follow-up is as outlined in Section2
(Schedule of Act ivities), Secti on9.2(Adverse Events), and Section 9.4(Safety) of the protocol.
8.2. Discontinuation from th e Study
In order to minimize the amount of missing data and to enable assessment of study  objectives as 
planned in the study  protocol , every attem pt will  be m ade to keep pati ents in the study
irrespect ive of the following:
I8F-MC-GPGM(b) Clinical Protocol Page 48
LY3298176adherence to study  drug
adherence to visit schedule
missing assessments
study  drug di scont inuat iondue to AE (Secti on 8.1.1)
development of comorbidit ies
development of clinical outcomes
The ci rcumstances listed above are not valid reasons for discont inuat ion from the study . 
Patients will  be discont inued in the following ci rcumstances:
enrollment in any other clinical study  involving an invest igational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study
participat ion in the study nee ds to be stopped for medical, safet y, regul atory , 
or other reasons consistent with applicable laws, regulat ions, and good clinical 
practi ce (GCP)
If a female pat ient beco mes pregnant
If a patient is diagnosed with T1D
M
patientrequests to be withdrawn from the study
Patients who agree to provide informat ion relevant to any  trial endpoint at the end of the study  
are not considered to have discontinued from the study .
A pat ient who withdraws consent and clearly indicate sthat there will be no further contact of any 
kind with the site will be considered to have discont inued fro m the study .
Prior to early  study  discontinuati on, the pati ent will discont inue study  drug and will have end-of-
study  procedures (ET vi sit) perf ormed as shown in the Schedule of Act ivities (Secti on 2).  
During the ET visit, the patient may be prescribed an appropriate glucose -lowering regimen and 
glucose self -monitoring plan. Visit 801 ( safety follow
-up visit) shoul d be perform ed 
approximately  4 weeks after the ET visit as the final study  visit.
Patients di scont inuing fro m the study  prem aturely for any  reason shoul d com plete AE and other 
safet y follow
-up per Secti on2(Schedule of Activit ies), Section 9.2(Adverse Events) ,and
Secti on9.4(Safet y) of this protocol .
8.3. Lost to Follow -up
A pat ient will be considered lost to fo llow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Every  attem pt will  be made to minimize 
the number of patients considered lost to fo llow-up at the end of the study .  Pati ents will be 
inform ed about the i mportance of complet ing the study  and provi ding updated contact 
inform ation to the study  site when necessary .
I8F-MC-GPGM(b) Clinical Protocol Page 49
LY32981769.Study  Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix 2 lists the lab oratory  tests that will be performed for this study .
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may 
be retai ned for a l onger peri od, if necessary , to comply  with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
9.1.1. Primary Efficacy Assessments and Procedures
The primary  efficacy  measurement in this study  is mean change in HbA1c from baseline to 
52weeks, as determined by the central laboratory .  Blood sam ples for HbA1c measurements will 
be co llected at specific clinic visits as summarized in the Study  Schedule .
9.1.2. Secondary Efficacy Assessments and Procedures
The fo llowing secondary  efficacy measures will be collected at the times shown in the Study  
Schedule.
Change in HbA1c fro m baseline
Change in weight from baseline
Proporti on of  patients achieving a target HbA 1c <7% (53 mmo l/mol)
9.1.3. Exploratory Efficacy Assessments and Procedures
The fo llowing secondary  efficacy measures will be collected at the times shown in the Study  
Schedule.
Fasting serum glucose measured in the central laboratory (actual values and change fr om 
baseline )
Seven -point SMBG profile (actual values and change from baseline to prespecified t ime 
points). Patients will be asked to perform two 7 -point SMBG profiles over a 24 -hour 
period, on nonconsecut ive days, during the 14 -day period pri or to each v isit, according to 
the Study  Schedule. The 7 -point profile consists of pre -meal and 2 -hour postprandial 
SMBG m easurements for the morning, midday, and evening meals in one day , and at 
bedtime. Pre-meal measurements should be taken before the patient begi ns eating the 
meal. Patients shoul d record their glucose measurements in their pat ient diaries, which 
are considered source documents and are to be returned to the invest igator at each study 
visit. Values fro m the 7-point SMBG profile will be transferred from the diary and 
recorded on the eCRF.
Chang e waistcircumference fro m baseline
I 8 F -M C - G P G M( b) Cli ni c al Pr ot o c ol P a g e 5 0 
L Y 3 2 9 8 1 7 6 9. 1. 4. A p pr o pri at e n e s s of A s s e s s m e nt s 
Efficac y a n d safet y assess me nts i ncl u de d i n t his st u d y  are ge nerall y  re gar de d as relia ble a n d 
acc urate wit h res pect t o t he efficac y a n d safet yassess me nts i n i n di vi d uals a n d p o p ulat i o ns wit h 
T 2 D M. 
9. 2. A d v er s e E v e nt s 
I n vest i gat ors are res p o nsi ble f or m o nit ori n g t he safet y of pat ie nt sw h o ha ve e ntere d t his st u d y  
a n d f or al erti n g Lill y  or i ts desi g nee t o a n y  e ve nt t hat see ms u n us ual, e ve n if t his e ve nt ma y be 
c o nsi dere d a n u na nt ic i pate d be nefit t o t he pati e nt .
T he i n vest i gat or is res p o nsi ble f or t he a p pr o priate me dical care of pat ie nt sd uri n g t he st u d y. 
I n vest i gat ors m ust d oc u me nt t heir re vie w of eac h la b orat or y  safet y  re p ort. 
T he i n vest i gat or re mai ns res p o nsi ble f or f o ll o wi n g, t hr o u g h a n a p pr o priate healt h care o pti o n, 
A Es t hat are seri o us or ot her wise me dicall y i m p orta nt, c o nsi dere d re lat e d t o t he i n vest i gat i o nal 
pr o d uct or t he st u d y , or t hat ca use d t he patie nt t o disc o nti n ue t he i n vest i gat i o nal pr o d uct bef ore 
c o m plet i n g t he st u d y.  T he pati e nt s h o ul d b e f ol l o we d u nt il t he e ve nt res ol ves or st a bilizes wit h 
a p pr o priate dia g n ostic e val uat i o n.   T he fre q ue nc y of f o ll o w- u p e val uat i o ns o f t h e A E i s left t o 
t h e discret i o n of t he i n vest i gat or. 
Lac k of dr u g effect is n ot a n A E i n cli nical st u dies, beca use t he p ur p ose of t he cli nical st u d y is t o 
esta blis h treat me nt effect. 
After t he i nf or me d c o nse nt f or m  ( I C F) is si g ne d, st u d y si te pers o n nel  will rec or d vi a t h e 
el e ctr o ni c case re p ort f or m ( eC R F )t h e occ urre nce a n d nat ure of eac h pati e nt ’s pree xist i n g 
c o n di ti o ns, i ncl u di n g cli nicall y  si g nifica nt si g ns a n d s y m pt o m s of t he disease u n der treat me nt i n 
t h e st u d y .  I n a d diti o n, si te pers o n nel  will  rec or d a n y  c h a n ge i n t he c o n dit i o n(s) a n d a n y ne w 
c o n di ti o ns as A Es .F or eac h A E, t he o nset a n d d urati o n, t he seri o us ness a n d se verit y,  a n d t he 
acti o ns ta ke n wi t h  res pect t o st u d y  treat m e nt will be rec or de d. I n vest i gat ors s h o ul d rec or d t heir 
assess me nt of t he p ote ntial relate d ness of eac h A E t o pr ot oc ol pr oce d ure, i n vest i g at i o nal pr o d uct, 
via t h eC R F .
Pr oce d ures a n d assess me nts perf or me d pri or t o Visit 3 are c o nsi dere d scree ni n g pr oce d ures . T he 
res ul ts of  t hese pr oce d ures a n d assess me nts s h o ul d be c o nsi dere d pre -e xist i n g c o n dit i o ns a n d 
s h o ul d be re p orte d as m e dical hist or y  or c o nc o mita nt ill ness.   
T he i n vest i gat or will i nter pret a n d d oc u me nt w het her or n ot a n A E has a reas o na ble p ossi bili t y  
of  bei n g relate d t o st u d y  treat m e nt, st u d y  de vice, or a st u d y  pr oce d ure, ta ki n g i nt o acc o u nt t he 
di sease, c o nc o mita nt treat me nt, or pat h ol o gies. 
A “reas o na ble p ossi bilit y” mea ns t hat t here is a ca use a n d effect relat i o ns hi p bet wee n t he 
i n vesti gat i o nal pr o d uct, st u d y  de vice ,a n d/ or st u d y  pr oce d ure a n d t he A E. 
T he i n vest i gat or a ns wers Yes or N o w he n ma ki n g t his assess me nt. 
Pl a n ne d s ur geries a n d n o ns ur gical i nter ve nt i o ns s h o ul d n ot be re p orte d as A Es u nless t he 
u n derl yi n g me dical c o n dit i o n has w orse ne d d ur i n g t he c o urse of t he st u d y. 
I8F-MC-GPGM(b) Clinical Protocol Page 51
LY3298176If a patient ’s investigational product is discontinued as a result of an AE, study site personnel 
must report this to Lilly or its designee via the CRF , clarifying if possible, the circumstances 
leading to any  dosagemodificati ons or di scont inuations of treatment.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dyi ng)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospitali zation but m ay jeopardi ze the patient or m ay require intervent ion 
to pr event one of the other outcomes listed in the definit ion above.   Examples of 
such m edical events include allergic bronchospasm requiring intensive treatment 
in an em ergency room  or at hom e, blood dy scrasias or ,convulsio ns that do not 
resul t in inpat ient hospi talizat ion, or the development of drug dependency  or drug 
abuse.
All AEs occurring after sign ing the ICF are recorded in the eCRF and assessed for serious 
criteria.  The SAE reporting to the sponsor begins after the pati ent has signed the ICF and has 
received invest igational product.  However, if an SAE occurs after signing the ICF, but prior to 
receiving invest igational product, the SAE should be reported to the sponsor as per SAE 
reporting requirements and timelines (see Sect ion9.2) if it is considered reasonably possibly 
related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ionrequi rement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.Patients with a serious hepat ic AEshoul d have addi tional data collected using the 
eCRF s (Secti on9.4.5.1 ).
Pregnancy ( during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements ,any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the patientdisposit ion eCRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he or she considers the event reasonably possibly related to 
the study  treatm ent or study  parti cipati on, the investigator must promptly notify Lilly.
I8F-MC-GPGM(b) Clinical Protocol Page 52
LY32981769.2.1.1. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigati onal product or procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Direct ive 2001/20/EC and the 
associ ated detailed guidance or nati onal regulatory requi rements in parti cipat ing countries 
requi re the reporting of SUSARs .  Lilly  has procedures that will be followed for the 
ident ificat ion, recording ,and expedited reporting of SUSARs that are consistent with global 
regul ations and the associated detailed guidances.
9.2.2. Adverse Events of Special Interest
9.2.2.1. Hypoglycemia 
Patients will co llect informat ion on epi sodes of hypoglycemia starting from Visit 2 until the last 
study  visit (Foll ow-up Vi sit or Early Terminat ion Visit).  For that purpose, patients will be 
trained about signs and symptoms o f hypoglycemia, how to treat hy poglyce mia, and how to 
collect appropriate informat ion for each episode of hy poglycemia in the study  according to the 
Schedule of Act ivities.  
Invest igators should use the fo llowing definit ions and criteria when diagnosing and categorizing 
an episode considered to be rel ated to hy poglycemia (the PGvalues in this sect ion refer to values 
determined by a laboratory  or Internati onal Federati on of  Clinical  Chemistry  and Laboratory  
Medicine blood -equivalent glucose meters and strips) in accordance with the 2017 Americ an 
Diabetes Association posit ion statem ent on glycemic targets (American Diabetes Associ ation
2017):
Glucose Alert Value (Level 1):
Documented symptomatic hypoglycemia is defined as any time a pat ient feels that he
or she is experiencing symptoms and/or signs associated with hypoglycemia and has a 
BG level of ≤70 mg/dL (≤3.9 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not accompanied by 
typical symptom s of hypoglycemia but with a measured BG ≤70 mg/dL ( ≤3.9 mmo l/L).
Documented unspecified hypoglycemia is defined as any event with no informat ion 
about symptoms of hypoglycemia available but with a measured BG ≤70 m g/dL 
(≤3.9 mmo l/L).
Clinically Significant Hypoglycemia (Level 2):
Documented sympt omatic hypoglycemia is defined as any time a pat ient feels that he
or she is experiencing symptoms and/or signs associated with hypoglycemia and has a 
BG level of <54 m g/dL (<3.0 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not acc ompanied by 
typical symptom s of hypoglycemia but with a measured BG <54 mg/dL (<3.0 mmo l/L).
Documented unspecified hypoglycemia is defined as any event with no informat ion 
about symptoms of hypoglycemia available but with a measured BG <54 m g/dL 
(<3.0 mmo l/L).
Severe hypoglycemia (Level 3):
I8F-MC-GPGM(b) Clinical Protocol Page 53
LY3298176Severe hypoglycemia is defined as an episode with severe cognit ive impairment
requi ring the assistance of another person to actively  administer carbohydrate, glucagon, 
or other resuscitative act ions.  These episodes may be associated with sufficient 
neuroglycopenia to induce seizure or coma. Bloodglucose measurements may not be 
available during such an event, but neurological recovery  attributable to the restoration of 
BG to norm al is considered sufficient evidence that the event was induced by  a low BG 
concentration.
Nocturnal hypoglycemia:
Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between 
bedtime and waking.
If a hypoglycemic event meets the criteria of severe, it shoul d be recorded as serious on the AE 
eCRF and reported to Lilly as an SAE.
To avoid duplicate reporting, all consecutive BG values ≤70 mg/dL (3.9 mmo l/L) occurring 
within a 1- hour period may be considered to be a single hypoglycemic event 
(Weinberg etal.2010; Danne et al. 2013).  
9.2.2.2. Severe, Persistent Hyperglycemia
Add-on glycemic rescue therapy  will be allo wed for pati ents who m eet any o f the following
prespecified criteria for severe, persistent hy perglycemia.  In thi s case ,the invest igator 
determines if a new intervent ion is warranted, after nonco mpliance with the assigned therapeutic 
regimen is ruled out as the reason for hy perglycemia. Patients shoul dcontinue administering 
assigned study  drugs (insulin glargine or LY3298176 ). The criteria are as fo llows:
a)average daily  BG from the QW 4-point SMBG profile >270 mg/dL (>15.0 mmo l/L) 
over at l east a consecutive 2 -week peri od any  time during the first 8 weeks post
rando mizat ion; 
OR 
b)average daily  BG from the QW 4-point SMBG profile >240 mg/dL (>13.3 mmo l/L) 
over a consecut ive 2 -week peri od at any  time 8to 16weeks post randomizat ion; 
OR
c)average daily  BG from the QW 4-point SMBG profile >200 mg/dL (>11.1 mmo l/L) 
over a consecut ive 2 -week peri od at any  time bey ond the fi rst 16weeks post
rando mizat ion
.
OR
d)HbA1c ≥8.5% (69 mm ol/mol) on 2 consecutive measurements separated by  at least 
8weeks at any  time bey ond the first 24 weeks post randomizat ion
Invest igators should first confirm that the patient is fully compliant with the assigned therapeutic 
regime n and that they  do not have an acute condit ion that is raising their BG. For patients in the 
insulin glargine arm, the above -described criteria for severe, persistent hy perglycemia will only  
be applicable after Week 12. The first cho ice before init iatingany rescue therapy  for those 
patients during the init ial 12 weeks will be to fo llow the TTT algorithm and to increase the dose 
I8F-MC-GPGM(b) Clinical Protocol Page 54
LY3298176of insulin glargine. This approach is reco mmended as first measure during the ent ire study  
course .  For patients who meet crite ria for severe persistent hy perglycemia, the invest igator will 
decide, in consultat ion with the pati ent, on an appropri ate gl ucose -lowering intervention (rescue 
therapy ).  Invest igators should fo llow nat ional standards of care for diabetes management in 
respective participat ing countries or the A merican Diabetes Associati on/European Associ ation 
for the Study  of Diabetes guidance (Inzucchi et al. 2015).  Glucagon -like pept ide-1receptor 
agonists, basal insulins, amylin analogs, and DPP-4 inhibitors are prohibited medicat ions and 
must not be included in the rescue intervent ion (with the exception of basal insulin in the 
LY3298176 arm).  Pati ents who receive a new intervent ion should also continue administering 
study  drugs for the rem aining period in the trial.
9.2.2.3. Pancreatitis
Acute pancreat itis is defined as an AE of interest in all trials with LY3298176 , including this 
trial.  Acute pancreat itis is an acute inflammatory  process of the pancreas that may also invo lve 
peripancreat ic tissues and/or remote organ sy stems (Banks and Freeman 2006).  The diagnosis of 
acute pancreatit is requires 2 of the fo llowing 3 features:
abdo minal pain, characterist ic of acute pancreat itis (generally located in the 
epigastri um and radi ates to the back in approximately half the cases ) (Banks 
and Fr eeman 2006; Koizumi et al. 2006) ; the pain is often assoc iated wi th 
nausea and vo miting)
serum  amylase (total and/or pancreatic) and/or lipase ≥3XULN
characterist ic finding s of acute pancreat itis on computed tomography  (CT) 
scan or magnet ic resonance imaging (MRI).
If acute pancreat itis is suspected, appropriate laboratory  tests (including levels of pancreat ic 
amylase and lipase) should be obtained via the central laboratory (and l ocally, if needed).  
Imaging studies, such as abdo minal CT scan with or without con trast, MRI, or gallbladder 
ultrasound, should be performed.  If laboratory  values and/or abdominal imaging support the 
diagnosis of acute pancreat itis, the patient mu st discontinue therapy  with LY3298176 but will 
continue in the study  on another gl ucose -lowering regimen.  The most appropriate diabetes 
therapeuti c regimen will be decided by the invest igator based on the patient’s clinical status.  A 
review of the patien t’s concomi tant medicat ions should be conducted to assess any potential 
causal relat ionship with pancreati tis.
Each AE of pancreat itis must be reported.  If ty pical  signs and/or symptoms of pancreatit is are 
present and confirmed by laboratory  values (lipas e or amylase [total and/or pancreatic]) and 
imaging studies, the event must be reported as an SAE.  For a potential case that does not meet 
all of these cri teria, it is up to the invest igator to determine the seriousness o f the case (AE or 
SAE) and the rel atedness of the event to study  drug(s).
Each patient will have measurements of p -amylase and lipase (assessed at the central laboratory) 
as shown on the Schedule o f Activities (Secti on 2)to assess the effects of the investigational 
doses of LY3298176 on pancreat ic enzyme levels. Serial measures of pancreatic enzymes have 
limited clinical value for predict ing episodes of acu
te pancreatit is in asymptomat ic pat ients 
I8F-MC-GPGM(b) Clinical Protocol Page 55
LY3298176(Nauck et al. 2017; Steinberg et al. 2017a; Steinberg et al. 2017b). Thus, further diagnost ic 
follow-up of  cases of asymptomat ic pancreat ic hyperenzymemia (lipase and/or pancreatic 
amylase ≥3XULN) is not mandated but m ay be perform ed based on the invest igator’s clinical 
judgment and assessment of the patient’s overall clinical condit ion.Only cases of pancreat ic 
hyperenzymemia that undergo additional diagnostic fo llow-up and/or are accom panied by 
symptoms suggest ive of pancreat itis will be submitted for adjudication.
All suspected cases of acute or chronic pancreat itis will be adjudicated by  an independent 
clinical endpo int committee ( CEC ). In addit ion, AEs of severe or serious abdo minal pain o f 
unknown et iology will also be submitted to the adjudicat ion commit tee to assess for possible 
pancreat itis or other pancreatic disease. Relevant data from patients with acute or chronic 
pancreat itis and those with severe or serious abdominal pain will be entered into a spec ifically 
designed eCRF page by study  site.The adjudicat ion committee representative will enter the 
resul ts of adjudicat ion in a corresponding eCRF page .
9.2.2.4. Thyroid Malignancies and C -Cell Hyperplasia
Individuals with personal or family history  of MTC and/or MEN- 2 will be excluded from the 
study .  The assessment of thyroid safet y during the tri alwill include reporting of any case of 
thyroid malignancy including MTC andpapillary carcino maand m easureme nts of calcit onin. 
This data will be captured in specific eCRFs. The purpose of calcitonin measurements is to 
assess the potential of LY3298176 to affect thy roid C-cell funct ion, which may indicate 
development of C -cell hyperpl asia and neopl asms. 
Patien ts with eGFR ≥60 m L/min /1.73m2 at Baseline
Patients who develop serum calcitonin increases ≥50% over the screening value AND an 
absolute value ≥20 ng/L and <35 ng/L will  be asked to repeat the measurement within 1 month.  
If this repeat value is increasing (≥10% increase), the pat ient will be encouraged to undergo 
additional endocrine assessment and longer term follow -up by an endocrino logist to excl ude a 
serious adverse effect on the gland.  
Patients wi th an increase in serum calcitonin ≥50% over the screening value AND an abso lute 
value ≥35 ng/L will be recommended to immediately undergo addit ional endocrine assessments 
and lo nger term  follow-up by  an endocrinol ogist.  If a patient’s labs meet this criteria, these 
clinically significant labs should be rec orded as an AE.  
For pati ents who requi re addi tionaQC Di d not see in Amendment summary nor Revised 
Protocol  Secti onsl endocrine assessment because of increased calcitonin concentration per 
criteria provi ded in this sect ion, data from the follo w-up asses sment will  be collected in the 
specific sect ion of the eCRF.
Patients with eGFR <60 m L/min /1.73m2 at Baseline
LY3298176 shoul d be discont inued (after first confirming the value) if postrando mizat ion
calcitonin value is ≥35 ng/L and has increased at least 50% over baseline. A consultat ion witha 
thyroid specialist (if not available, an endocrino logist) shoul d be obtained. 
I8F-MC-GPGM(b) Clinical Protocol Page 56
LY3298176If the increased calcitonin value ( ≥35 ng/L and increases by  ≥50% com pared to baseline) is 
observed in a patient who has been administered a medicat ion that i s known to increase serum 
calcitonin , then this m edicat ion should be stopped and calcitonin levels should be measured after 
an appropriate washout period.
For pati ents who requi re addi tional endocrine assessment because of increased calcitonin 
concentration per criteria provided in this sect ion, data from the fo llow-up assessment will be 
collected in the specific section o f the eCRF.
9.2.2.5. Major Adverse Cardiovascular Events
Deaths and nonfatal CV AEs will be adjudicated by  a commi ttee of  physicians external to Lilly 
with cardi ology expertise.  This committee will be blinded to treatment assignment.   The 
nonfatal  CV AEs to be adjudicated include MI; hospitalization for unstable angina; 
hospi talization for heart failure; coronary  interventio ns (such as coronary  artery  bypass graft or 
percutaneous coronary  intervent ion); and cerebrovascular events, including cerebrovascular 
accident (stroke) and transient ischemic attack.
9.2.2.6. Supraventricular Arrhythmias and Cardiac Conduction Disorders
Treatment -emergent cardiac conduction disorders will be further evaluated. Patients who 
develop any event from these groups of disorders should undergo an electrocardiogram (ECG )
which should be submitted to th e central  reading center. Addit ional diagnostic tests to determine 
exact di agnosis shoul d be perform ed, as needed. The specific diagnosis will be recorded as an 
AE. Events that meet criteria for serious condit ions as described in Section 9.2.1 must be 
reported as SAEs. 
9.2.2.7. Hypersensitivity Events
All allergic or hy persensi tivity react ions will be reported by the invest igator as either AEs or, if 
any serious criterion is met, as SAEs.  Addit ional data, such as type of reaction and treatment 
received, will be collected on any AEs or SAEs that the inv estigator deem s related to study  
drug(s) vi a the eCRF created for this purpose.  Addit ional samples should also be collected as 
outlined in Section 9.4.4 .  Study  drug(s) shoul d be tem porarily interrupted in any individual 
suspected of having a severe or serious allergic reaction to study  drug(s).  Study  drug(s) m ay be 
restarted when/if it is safe to do so, in the opinio n of the invest igator.  If stud y drug(s) i s 
perm anent ly discont inued, the patient will receive another glucose -lowering treatm ent, j udged by 
the invest igator to be appropriate based on the patient’s clinical status, and will cont inue in the 
trial to collect all plan ned efficacy and safe ty measurem ents.
9.2.2.7.1. Injection Site Reactions
Inject ion site reactions will be co llected on theeCRF separate from the hypersensit ivity react ion 
eCRF. At the time of AE occurrence in the LY3298176 arm, samples will be co llected for 
measurement of LY3298176 ADA and LY3298176 concentration.
9.2.2.7.2. Anti-Drug Antibodies
The occurrence of ADA formation will be assessed as outlined in Section 9.4.4 . 
I8F-MC-GPGM(b) Clinical Protocol Page 57
LY32981769.2.2.8. Diabetic Retinopath yComplications
Dilated r etinal fundoscopi c exam will be performed by an eye care professio nal (ophthalmo logist 
or optom etrist) forall pat ients between Visit 2and Visit 3 to exclude pat ients with proliferat ive 
retinopathy  and/or m aculopathy .  The resul ts from this exam  will be recorded on a specific
retinopathy eCRF as a baseline measure of retinopathy .  
A follow-up, dilated fundoscopic exam shoul d be perform edwhen clinically indicated by any 
adverse event suspected of worsening retinopathy , and the findings should be recorded on the 
retinopathy  eCRF.  
9.2.2.9. Hepatobiliary Disorders
All events of TE biliary  colic, chol ecyst itis, or oth er suspected events related to gallbladder 
disease shoul d be evaluated and addit ional diagnostic tests performed, as nee ded.  
In cases of 
elevated liver m arkers, hepati c monitoring shoul d be init iated as outlined in Sect ion 9.4.5.1 and
Appendix 4 .
9.2.2.10. Severe Gastrointestinal Adverse Events
LY3298176 may cause severe GI AEs, such as nausea, vo miting, and diarrhea.  Informat ion 
about severe GI AEs as well as antiemetic/antidiarrheal use will be co llected in the eCRF/AE 
form.  For detailed information concerning the management of GI AEs, please refer to
Secti on7.7.1 .
9.2.2.11. Acute Renal Events
Renal safety  will be assessed based on repeated renal funct ional assessment as well as 
assessment of AEs suggest ive o f acute or worsening of chronic renal failure .GI AEs have been 
reported with LY3298176, including nausea, diarrhea, and vomit ing. This is consistent with 
other GLP -1 receptor agonists (Aroda and Ratner 2011). The events may lead to dehydrat ion, 
which coul d cause a deteri oration in renal funct ion, including acute renal failure. Patients shoul d 
be advised to notify  investi gators in case of severe nausea, frequent vomit ing, or symptoms of 
dehydrat ion.
9.2.2.12. Metabolic Acidosis, Including Diabetic Ketoacidosis 
Ketoaci dosis, a seri ous life -threatening condit ion requiring urgent hospitalizat ion,hasbeen 
reported rarely in patients with T2DM .  Patients who present with signs and symptoms consistent 
with severe metabolic acidosis shoul dbe assessed for ketoaci dosis regardl ess of present ing blood 
glucose l evels, as ketoacidosis may  be present even if blood glucose levels are less than 250 
mg/dL. If ketoacidosis is suspected, SGLT2is shoul d be di scontinued (if used) , pati entsshoul d 
be evaluated, and prom pt treatm ent shoul d be inst ituted. 
Treatment of ketoacidosis may require 
insulin, fluid, and carbohydrate replacement.
Lactic acidosis ha sbeen reported rarely  in patients wi th T2DM associ ated wi th use of  
metformin, excessive alcoho l intake,anddecreasedrenal funct ion.Routine bicarbonate 
assessment will be performed during the course of the study .  If lactic acidosis is suspected, 
metformin should temporarily be discont inued (if used) unt il the reso lution of the event.
I8F-MC-GPGM(b) Clinical Protocol Page 58
LY32981769.2.2.13. Amputation /Peripheral Revascularization
All cases of amputation and peripheral revascularization shoul dbe reported as an AE.
9.2.2.14. Major Depressive Disorder /Suicidal Ideation
The prevalence of depressive symptoms and disorders is increased in pat ientswith T1DM or 
T2DM (ADA 2017). Any AEof major depressive disorder or suicidal ideat ion shoul d be 
reported.
9.2.3. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, to monitor qualit y, and to 
facilitate process and product improvements.
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation can b e assessed.
9.3. Treatment of Overdose
Study  drug overdose (more tha n the specified number and dose of inject ions) will  be reported as 
an AE. In the event of overdose, r efer to the IBfor LY3298176 and/or Product Label for insulin 
glargine (Basaglar USPI ,2015 [WWW]).
9.4. Safety
9.4.1. Electrocardiograms
For each patient, ECGs should be co llected according to the Schedule of Activit ies (Secti on 2).  
Electrocar diograms should be recorded according to the study -specific reco mmendat ions 
included in Manual o f Operati ons f or the study .  
Electrocardiograms will init ially be interpreted by  a qualified physician (the investigator or 
qualified designee) at the site as soon after the time of ECG collection as possible, and ideally 
while the patient is st ill present, for immediate subject management, should any clinically 
relevant findings be identified .  
Any clinically significant findings fro m ECGs that result in a 
diagnosis and that occur after the pati ent receives the first dose of the invest igational treatment 
shoul d be reported to Lilly or its designee as an AE via the eCRF.
All digital ECGs will be obtained using centrally provided ECG machines and will be 
electroni cally transmitted to a designated central ECG laboratory .The central ECG laboratory  
will perform a basic qualit y control  check ( for example , dem ographics and study  details) and 
then store the ECGs in a database. At a future time, the stored ECG data may be overread by a 
cardi ologist at the central  ECG l aboratory  for further evaluat ion of machine -read measurements 
or to m eet regul atory  requi rements. The m achine -read ECG intervals and heart rate may be used 
for data analysis and report -writing purposes, unless a cardiologist overreading of the ECGs is 
conducted pri or to com pletion of the final study  report (in which case, the overread data would 
be used).
I8F-MC-GPGM(b) Clinical Protocol Page 59
LY32981769.4.2. Vital Signs
For each patient, vital signs measurements should be conducted according to the Schedule o f 
Activities (Secti on 2) and fo llowing the study -specific reco mmendat ions included in the Manual 
of Operati ons for the study .
Any clinically  significant findings from vital signs measurement that result in a diagnosis and 
that occur after the patient receives the first dose of study treatment should be reported to Lilly or 
its designee as an AE via the
eCRF .
9.4.3. Laboratory Tests
For each patient, l aboratory  tests detailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Act ivities (Secti on 2). 
With the exception o f laboratory  test resul ts that may  unblind the study , Lilly or its desi gnee will 
provi de the invest igator with the results of laboratory  tests analyzed by  a central vendor, if a 
central vendor i s used for the clinical trial.  
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the pati ent receives the first dose of invest igatio nal product should be reported to Lilly or its 
designee as an AE via the
eCRF .
9.4.4. Immunogenicity Assessments 
Where local regulat ions and ERBs allow, blood samples for immunogenicit y testing will be 
collected to determine ant ibody  producti on against LY3298176 as specified in the Schedule of 
Activities (Section 2).
At the visit s and t imes specified in the Schedule of Act ivities (Secti on 2), venous blood samples 
will be co llected to determine ant ibody  producti on against the LY3298176 .  To interpret the 
resul ts of immunogenicit y, a PK samplewill be collected at the same time points as the 
immunogenicit y sample .  All samples for immunogenicit y shoul d be taken predose when 
applicable and possible.  In the event of systemic drug hy persensi tivity react ions (immediate or 
nonimmediate), additional samples will be co llected (including ADA, PK ,and,exploratory  
immune safet ysample ) as close to the onset of the event as possible, at the resolut ion of the 
event, and 30 day s following the onset of the event.  Instructions for the collect ion and handling 
of blood sam ples will  be provi ded by the sponsor.  The actual date and time (24 -hour clock time) 
of each sampling will be recorded.  Immunogenicit y will be assessed by a validated as say 
designed to detect ADAs in the presence o f the LY3298176 at a l aboratory  approved by the 
sponsor.  Sample co llected at Visit 801 will assess immunogenicit y at washout of LY3298176 (5 
half-lives post end of treatment).
Treatment -emergent ADAs are define d in Sect ion 10.3.6 .
Samples wi th LY3298176 ADA detected will be titered and evaluated for their abilit y to
neutralize the activit y of assigned treatm ent (
LY3298176 -neutralizing ant ibodies). Samples with 
LY3298176 ADA detected will also be tested for cross -reactive binding to native GIP and GLP -
I8F-MC-GPGM(b) Clinical Protocol Page 60
LY32981761, and, if such is detected, then for neutralizing antibodies against nat ive GIP and GLP -1, 
respectivel y
.
Samples will  be retained for a m aximum  of 15 y ears after the last patient visit, or for a shorter 
period if local  regulat ions and Ethical Review Boards (ERBs) allow, at a facilit y selected by  the 
sponsor.  The duration allows the sponsor to respond to f uture regulatory  requests rel ated to 
LY3298176 .  Any samples remaining after 15 y ears will  be destroy ed.
9.4.5. Safety Monitoring 
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
methods.
9.4.5.1. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or TBL ≥2X ULN, liver 
testing ( Appendix 4 ) shoul d be repeated wi thin 3 to5 days including ALT, AST, ALP, TBL, 
direct bilirubin , gamma- glutamyl transferase, and creatine kinase to confirm  the abnorm ality and 
to determine if it is increasing or decreasing.  If the abnormalit y persists or worsens, clinical and 
laboratory  monitoring shoul d be ini tiated by  the investi gator and in consultat ion with the study  
medical mo nitor.Monitoring of ALT, AST, TBL ,and ALP should continue unt il levels 
norm alize or return to approximate baseline levels. 
Hepatic Safety Data Collection
Addit ionalsafet y data should be co llected via the eCRF if 1 or more of the fo llowing condi tions 
occur :
elevation of serum  ALT to ≥5X ULN on 2 or more consecutive blood tests
elevated serum TBL to ≥2X ULN (except for cases of known Gilbert’s 
syndro me)
elevation of serum  ALPto ≥2X ULN on 2 or more consecutive blood tests
patient discont inued fro m treatm ent due to a hepatic event or abnormalit y of 
liver tests
hepatic event considered to be a SAE
9.5. Pharmacokinetics
Pharmacokinet ic samples will be co llected from the first 150 patients ineach LY3298176 arm,
all patients age d≥70 y ears, and all pat ients with severe renal impairment or ESRD
(eGFR<30 m
L/min). 
Plasma LY3298176 concentrations will be determined fro m blood samples obtained from  
patients receiving LY3298176 treatm ent.Blood samples for PK assessment will be co llected 
after 7, 15, 23, and 35weeks of LY3298176 treatment per the Study Schedule or at early  
termination (reference to SoA) .  Each patient will be assigned viaIWRSto one of the sampling 
PK time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours post dose at Weeks 7, 15, 
23,and 35.
I8F-MC-GPGM(b) Clinical Protocol Page 61
LY3298176The date and time of the most recent SCinject ion administered prior to collect ing the sample 
must be recorded on the eCRF fro m the study  diaries.
The date and time at whi cheach sample was drawn must be recorded on the laboratory  accessi on 
page. 
Concentrations of LY3298176 will be assayed using a validated liquid chro matography  mass 
spectrometry  (LC/MS) method.
Bioanaly tical samples collected to m easure LY3298176 concentrations will be retained for a 
maximum o f 1 year following l ast pati ent visi t for the study .
9.6. Pharmacodynamics
Samples to assess the PDproperties of LY3298176 are included in the efficacy measures and not 
applicable in this sect ion.
9.7. Pharmacogenomics
9.7.1. Whole Blood Samples for Pharmacogenetic Research
A whole blood sam ple will  be collected for pharmacogenet ic analysis as specified in the 
Schedule of Act ivities (Secti on2)where local regulat ions allow .  
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate vari able response to LY3298176 and to 
investigate genet ic variants though t to pl ay a rol e in T2DM.   Assessment of variable response 
may include evaluation o f AEs or differences in efficacy .  
All samples will be coded with the patient number.  These samples an d any data generated can 
be linked back to the patient only by the invest igator site personnel .  
Samples will  be retained at a facilit y selected by  Lilly  or its designee for a m aximum  of 15years 
after the l ast pati ent vi sit for the study  or for a shorter period if lo cal regulat ions and/or Ethical 
Review Boards ( ERBs )/invest igational review boards ( IRBs )impose shorter time limit s.  Thi s 
retenti on peri od enables use o f new techno logies, response to regulatory  quest ions, and 
investigat ion of variable respon se that m ay not be observed unt il later in the devel opment of 
LY3298176 or after LY3298176 beco me(s) commercially available .
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  Howev er, exist ing approaches include who le geno me or exome 
sequencing, geno me-wide associ ation studies, and candidate gene studies.  Regardless of 
techno logy utilized ,genoty ping data generated will be used only for the specific research scope 
described in this section. 
9.8. Biomarkers
Biomarker research is performed to address questions of relevance to drug di sposi tion, target 
engagement, PD, mechanism of act ion, variabilit y of patient response (including safety ), and 
I8F-MC-GPGM(b) Clinical Protocol Page 62
LY3298176clinical outcome.  Sample co llection is incorp orated into clinical studies to enable examinat ion of 
these quest ions through measurement of bio molecul es including proteins, lipids, and other 
cellular elements.
Serum andplasma samples for nonpharmacogenetic biomarker research will be co llected at the 
times specified in the Schedule of Act ivities (Section 2)where local regulat ions allow.
Samples will  be used for research on the drug target, disease process, variable response to 
LY3298176 , 
pathway s associ ated wi thT2DM,mechanism o f action of  LY3298176 , and/or 
research method or in validat ing diagnost ic tools or assay(s) related to T2DM.  
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by the invest igator site personnel .  
Samples will  be retained at a facilit y selected by  Lilly  or its designee for a m aximum  15 years 
after the l ast pati ent vi sit for the study  or for a shorter peri od if lo cal regulat ions and ERBs 
impose shorter time limits.   This retention period enables use of new technologies, response to 
regul atory  questi ons, and invest igation of variable respo nse that may not be observed unt il later 
in the course of the development and commercialization of both study  drugs.
9.9. Health Economics
The fo llowing quest ionnaires will be completed by the patients at specific clinic visit s according 
to the Schedule of Eve nts (Section 2). At these visits, the questionnaires should be co mpleted 
before the patient has discussed their medical condit ion or progress in the study  with the 
investigator and/or site staff and before any other study  procedures if the pat ient is not adversely 
affected by  their fast ing condit ion
.
9.9.1. European Quality of Life (EQ -5D-5L)
Generic HR -QoL will  be assessed using the E Q-5D-5L(EQ-5D; Euro QoL Group 2015 ).  The 
EQ-5D-5L is a standardized 5-item instrument for use as a measure of health outcome.  It 
provi des a simple descriptive profile and a single index value for health status that can be used in 
the clinical and econo mic evaluat ion of heal thcare as well as populat ion healt h surveys.  The 
EQ-
5D-5L comprises 5 dimensio ns of health (mobilit y, self-care, usual act ivities, 
pain/disco mfort, and anxiet y/depressi on).  The 5L versio n, introduced in 2005, scores each 
dimensio n at 5 l evels (no proble ms, slight problems , moderate problems , severe probl ems, 
unable to perform/ extrem e probl ems), for a total  of 3251 possible health states.  In addit ion to the 
healt h profile, a single healt h state index value can be derived based on a formula that attaches 
weights to each of the levels in each dimensio n. This index value ranges between l ess than 0 
(where 0is a health state equivalent to death; negative values are valued as worse than dead) to 1 
(perfect health).   In addit ion, the EQ Visual Analo g Scal erecords the respondent ’s self -rated 
healt h status on a vertical graduated (0 to 100) visual analogscale.  In conjunct ion with the 
healt h state data ,it provi des a co mposite picture of the respondent ’s healt h status.  
I8F-MC-GPGM(b) Clinical Protocol Page 63
LY3298176The EQ -5D-5L is used worldwide and is available in more than 170 different languages.  Details 
on the instrument, and scoring, organizing, and presenting the data collected can be found in the 
EQ-5D-5L User Guide (EuroQoL Group 2015). 
9.9.2. Ability to Perform Physical Acti vities of Daily Living (APPADL) 
The Abilit y to Perform  Physical  Activities of Daily Living (APPADL) quest ionnaire contains 7 
items that assess how difficult it is for patients to engage in certain act ivities considered to be 
integral  to norm al daily  life, such as walking, standing, and climbing stairs (Hayes et al . 2011; 
Hayes et al . 2012).  Item s are scored on a 5 -point numeric rating scale, where 5 =“not at all 
difficult” and 1 =“unable to do.”  A raw overall score is calculated by  simply  summing the 
scores of the 7 i tems, and a transformed overall score is obtained by  linearly  transf orming the 
raw overall score to a 0 to 100 scale.  A higher raw overall score and a higher transform ed 
overall score are indicat ive of better abilit y to perform  activit ies of daily living.  
9.9.3. Impact of Weight on Self -Perception Questionnaire (IW -SP)
The Im pact of  Weight on Self -Percept ion (IW -SP) questionnaire contains 3 items that assess 
how often the patients’ body  weight affects how happy  they  are wi th their appearance and how 
often they  feel self-consci ous when out in public (Hay es and DeLozi er 2015).  Each i tem is rated 
on a 5 -point scale ranging fro m “always” to “never.”  Total scores for the IW -SP are derived by 
summing the item scores and dividing by the number of item s.  The score can also be 
transformed to a range fro m 0to100.  Higher IW -SP scores correspond to better self -percept ion 
(Hay es and DeLozi er 2015).
9.9.4. Diabetes Treatment Satisfaction Questionnaire (DTSQ)
The status (s) and change (c) versio ns of the Diabetes Treatment Satisfact ion Quest ionnaire 
(DTSQ) will be used during the study  to assess the pati ents’ sat isfaction with their diabetes 
treatm ent and the perceived frequency of hyperglycemia and hypoglycemia. The questionnaire 
contains 8 items (Bradley 1994). Each i tem is rated on a 7- point Likert scale. Six items (1 and 4 
through 8) are summed to produce a measure of treatm ent sati sfact ion ranging fro m 0 “very 
dissatisfied”to 6 “very satisfied .”The remaining 2items (2 and 3) are treated individually.  Item 
2 measures the perceived frequency of hyperglycemia on a scale ranging from 0 “none of the 
time” to 6 “most of the time, ”and Item 3 measures the perceived frequency  of hypoglycemia on 
the sam e scale.  The change versio n has the same 8 items as the status versio n with a small 
alterati on of  the wording of Item 7. The DTSQc response options differ fro m those of  the 
DTSQs to produce measures o f relative change rather than absolute satisfact ion.
I8F-MC-GPGM(b) Clinical Protocol Page 64
LY329817610.Statistical Considerations
10.1. Sample Size Determination
Patients will  be randomized in a 1:1:1:3 ratio to 5 mg LY3298176 , 10mg LY3298176 ,15 m g 
LY3298176 ,and insulin glargine to optimize CVrisk assessment of LY3298176 .
Although the primary object ive is to establish noninferiorit y, sample size select ion is guided by 
the object ive of establishing superiorit y of each LY3298176 dose to insulin glargine relat ive to 
the reduction in mean HbA1c change fro m baseline at 52 weeks from rand omization irrespect ive
of adherence to i nvest igational product or introduction of rescue therapy  for persi stent severe 
hyperglycemia (“treatm ent-regimen” est imand).  
The sample size determinat ion assumes that evaluation of superiorit y of 10 m g LY3298176 and 
15mg LY3298176 to insulin glargine will be conducted in parallel , each at a 2-sided 
significance l evel of 0.025 using a 2-sample t-test.  Addit ionally, a 0. 30% superior mean HbA1c 
reducti on from baseline at 52weeks fro m rando mization for 10 m g LY32981 76and 15 m g 
LY3298176 compared to insulin glargine and a commo n standard deviat ion (SD) of 1.3% are 
assumed for statist ical power calculat ions.  Under the assumptions above, randomizing 1878 
patients in a 1:1:
1:3ratio to 5 mg LY3298176 (313 patients), 10mg LY3298176 (313 patients),
15 m g LY3298176 (313 patients) ,and insulin glargine (93 9patients) provi des 90% power to 
demonstrate superi ority of each LY3298176 dose to insulin glargine. 
The chosen sample size and rando mization ratio also provides >90% p ower to establish 
superi ority of 10 m g LY3298176 and 15 m g LY3298176 doses to insulin glargine in absence of 
confounding effects of rescue therapy  for persi stent severe hyperglycemia (“efficacy” est imand).  
For c omparison of each LY3298176 dose to i nsulin glargine using data collected prior to the 
initiation of any rescue medicat ion or premature treatment discont inuat ion, conducted in parallel 
using a 2-sample t -test, each at a 2 -sided significance level of 0.025, a 0.30% superior mean 
HbA1 c reduct ioncompared to insulin glargine, a commo n SD of 1.1%, and no more than 28% 
initiate of any rescue antihyperglycemic medicat ion or prematurely discont inue study  drug by 52
weeks are assumed
.
The tri al is designed to contribute toward a meta -analysi s across Phase 3 trials dem onstrating that 
LY3298176 treatm ent is not associated with excessive CV risk.  The ant icipated treatment 
allocat ion of pool ed LY3298176 versus pool ed comparator is 3:1in other LY3298176 Phase 3 
clinical trials. The primary  measure of CV ri sk is the hazard rate of CEC that confirmed 4 -
component MACE -4: CV death, myocardial infarction (MI), stroke, and hospitalizat ion for 
unstable angina.  Under the assumpt ion of no increase or decrease in CV risk wit h LY3298176
compared to pool ed com parator ,approximately 13 3patients wi th MACE -4 events arerequired 
to have 90% power to ensure that the upper 95% confidence limit for the hazard ratio is less than 
1.8in the meta -analysis .  Assuming 33 to 40 pati ents wi th MACE -4 events per 1000 patient 
years of exposure and 2% reduced exposure due to lost to follow -up, pati ents fo llowed for an 
average o f 18 to 22 months is expected to resul t in 110pati
ents with MACE -4 events. 
I8F-MC-GPGM(b) Clinical Protocol Page 65
LY329817610.2. Populations for Analyses
For purposes of analysis, the following analysis sets are defined in Table GPGM. 5below :
Table GPGM. 5. Description of Analysis Sets
Analysis Set Description
Screened patients All participants who sign informed consent
Randomized patients All patients who are randomly assigned a treatment arm
modified intention -to-treat 
(mITT) setAll randomly assigned participants who are exposed to at least 1dose of study 
drug.
Efficacy analysis set(EAS) Data obtained during Study Period II and III from mITT, excluding data after 
initiating rescue anti hyperglycemic medicatio n or stopping study drug (last 
dose date + 7 days). In the event of a treatment error, participants will be 
analy zed according to the treatment they were randomized .
Full analysis set (FAS) Data obtained during Study Period II and III from mITT, regardless of 
adherence to study drug or initiation of rescue anti hypergly cemic medication. 
Safety analysis set (SAS) Data obtained during both Study Period II, III, and IV from mITT, regardless 
of adherence to study drug or initiation of rescue anti hyperglycemic
medication.
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly orits designee. Any change to 
the data analysis methods described in the protocol will require an amendment ONLY if it 
changes a principal feature of the protocol.  Any  other change to the data analysis methods 
described in the protocol, and the just ificat ion for making t he change, will be described in the 
statist ical analysis plan (SAP) or the clinical study  report (CSR). Addit ional exploratory  data 
analyses may be conducted as deemed appropriate.
Unless otherwise noted, all tests of treatment effects will be conducted a t a 2-sided alpha level o f 
0.05,and the confidence interval ( CI)will be calculated at 95%, 2 -sided. In statist ical 
summaries and analyses, patients will  be analyzed as randomized.
There will be 2estimands o f interest in comparing efficacy o f LY3298176 doses wi th insulin 
glargine. First estimand, the “efficacy” est imand, represents efficacy prior to discont inuat ion of 
study  drug wi thout confounding effects of ant ihyperglycemic rescue therapy .  Second estimand, 
the “treatm ent-regimen” est imand, represent s the efficacy  irrespect ive o f adherence to study  drug 
or init iation of rescue antidiabetic drugs.  
The primary  efficacy  assessment, gui ded by the “efficacy” est imand, will be conducted using 
EAS. The primary efficacy assessment, guided by the “treatm ent-regimen” est imand, will be 
conducted using FAS .As they are intended for different purposes, n o multiplicity adjustments 
will be made for conducting 2primary efficacy assessments .
Unless specified otherwise, safet y assessments will be guided b y an estimand co mpar ing safety  
of LY3298176 doses wi th insulin glargine irrespective of adherence to study  drug or ini tiation of 
I8F-MC-GPGM(b) Clinical Protocol Page 66
LY3298176antihyperglycemic rescue therapy . Thus, safety  analysis will be conducted using safety  analysis 
set(SAS) .  Selected safet y analysis may be conducted after excluding data on rescue therapy .  
Summary  statistics for continuous m easures will  include sample size, mean, SD, median, 
minimum, and maximum.  Theanalysis model to make co mpar isons amo ng treatment arms 
relative to continuo us m easurements assessed over time will be a mixed model for repeated 
measures (MMRM), with terms: treatm ent, visit, and treatment -by-visit interaction ,country , 
SGLT -2iuse (Yes orNo), and baseline measurement as a covariate. An unstructured covariance
structure will model relat ionship of wit hin-patient errors.
Kaplan -Meier m ethod will be used for estimation of cumulat ive event -freesurvival  rates over 
time, and cox proportional hazards regression analysis will be used to compare hazard rates 
among treatm ents.
Summary  statistics for categorical measures (including categorized continuous measures) will 
include sample size, frequency, and percentages. Fisher’s exact test will be used to examine the 
treatm ent difference in categorical outcomes. Logist ic regression may be used to examine the 
treatm ent difference in binary  efficacy  outcomes. Summary  statistics for discrete coun t 
measures will include sample size, mean, SD, median, minimum, and maximum. The negat ive 
binomial regressio n model will be use d for the treatm ent com parison of discrete count measures. 
Other stati stical methods may be used, as appropriate, and details will be documented in the 
SAP.
10.3.2. Treatment Group Comparability
10.3.2.1. Patient Disposition
Frequency counts and percentages of all pat ientsscreened, rando mized ,and receiving at least 1
dose of study  drug will be presented by  treatm ent groups.  A list ing of rando mized patients not 
receiving study  drug will be provided. Of the patients in modified intent ion-to-treat (mITT)set, 
frequency  counts and percentages of pat ients com pleting the study, prematurely discont inuing 
the study , including reason for premature discontinuation, will be presented by  treatm ent groups. 
A Kaplan -Meier analysis o f time fro m rando mizat ion to prem ature di scontinuat ion from study  by 
treatm ent group will be provided.  
10.3.2.2. Patient Characteristics
Dem ographic, m edical history , and conco mitant illness will be summarized by treatment group, 
using the mITT set. 
10.3.2.3. Concomitant Therapy 
Concomitant medicat ions,including previous therapy for diabetes, will be summarized by 
anatomical therapeut ic chemical classificat ion and treatment arm using the mITT set.  In 
particular, the incidence of init iation of rescue therapy  for severe, persistent hy perglycemia will 
be analyzed as an exploratory  safet y endpoint. Dose modificat ionsof oral antihyperglycemic 
therapy  will also be compared between treatment arms.
I8F-MC-GPGM(b) Clinical Protocol Page 67
LY329817610.3.2.4. Treatment Compliance 
Of the pati ents in m ITT set, frequency  counts and percentages of pat ients prematurely 
discontinuing study  drug, including reason for premature discont inuat ion, will be presented by 
treatm ent groups.  A Kaplan -Meier analysis o f time fro m rando mizat ion to prem ature study  drug 
discontinuat ion by treatment group will be provided.
Treatment complian ce for each visi t interval is defined as taking at least 75% of required
inject ions of study  drugs. Frequency counts and percentages ofpatients com pliant to study  drug 
will be summarized by  treatm ent arms and visits using the m ITT set .
10.3.3. Efficacy Analyses
10.3.3.1. Primary Analyses
As indicated in Section 10.3.1 , there will be 2primary  efficacy analyses conducted to establish 
noninferiorit y of 10mgLY3298176 and 15 mg LY3298176 to insulin glargine relat ive to mean 
change in HbA1c from baseline to 52-week visit .
For the FDA, t he primary  efficacy  analysis will be guided by  the “ treatm ent-regimen ” estimand 
defined in S ection 10.3.1 .  This assessment will analyze change in HbA1c values obtained at 
52-week visit using an analysis o f covariance (ANCOVA) with terms, treatm ent, stratificat ion 
factors, and baseline HbA1c as a covariate .  Missing change in HbA1c fro m baseline values at 
52-week visit will be imputed based on observed changes in HbA1c fro m baseline values at the 
visit fro m patients in the same treatment arm who ha d thei r efficacy  assessed after early 
discontinuat ion of study  drug and/or init iation of rescue antihyperglycemic medicat ion.  With the 
aid of the ANCOVA, 2- sided 97.5% CI for the difference in mean change in HbA1c from 
baseline to 52 -week visit between 10 mg LY3298176 and insulin glargine as well as between 
15mg LY3298176 and insulin glargine will be constructed.  Analysis will be conducted with 
multiple imputations ,and statistical inference over mult iple imputations will be guided by  the 
method proposed by  Rubin (1987).  If the upper limit of the CI is below 0.3%, LY3298176 dose 
will be declared noninferior to insulin glargine.
For all other purposes, t he primary efficac y analysis will be guided by the “e fficacy” est imand 
defined in S ection 10.3.1 . This assessment will be conducted using EAS. Theprimary analysis
model for HbA1c m easurements over time will be a nMMRM. The response variable o f 
MMRM will be change in HbA1c fro m baseline values obtained at each scheduled postbaseline 
visit.  The independent variables of the MMRM model are treatm ent group ( 5 mgLY329 8176, 
10 m gLY3298176
,15 m g LY3298176 ,and i nsulin glargine), visit, and treatment -by-visit 
interact ion, country , SGLT -2i use ( YesorNo), and baseline HbA1c as a covariate.  An 
unstructured covariance structure will model relat ionship of wit hin-patient e rrors. If the analysis 
fails to converge, the fo llowing variance -covariance m atrix will be used (in order) until 
convergence is achieved :heterogeneous compound symmetry ,compound symmetry ,and first-
order autoregressive.  The Kenward -Roger approximat ion will be used to estimate deno minator 
degrees of freedo m. With the aid o f the MMRM analysis, 2 -sided 97.5% CI for the difference in 
mean change in HbA1c from baseline to 
52-week visit between 10mg LY3298176 and insulin 
glargine as well as between 15 mg LY3298176 and insulin glargine will be constructed.  If the 
I8F-MC-GPGM(b) Clinical Protocol Page 68
LY3298176upper limit of the CI is below 0.3%, LY3298176 dose will be declared non inferior to insulin 
glargine.
10.3.3.2. Secondary Analyses
The secondary  study obj ectives subject to type 1 error rate control areas fo llows: 
noninferiorit y of 5mgLY3298176 dose to insulin glargine relat ive to mean change in 
HbA1c fro m baseline to 52-week visit
superi ority of each LY3298176 dose to insulin glargine relat ive to mean change in 
HbA1c fro m baseline to 52-week visit
superi ority of each LY3298176 dose to insulin glargine relat ive to mean change in body  
weight from baseline to 52-week visit
superi ority of each LY3298176 dose to ins ulin glargine relat ive to proportion of patients 
achieving target value o f HbA1c <7% at 52
-week visit
Type 1 error -controlled strategy  for primary  and secondary  endpoints will be described in the 
SAP.  All type 1 error -controlled secondary  efficacy  analyses will be conducted relat ive to both
estimands, the “efficacy” est imand and the “treatment -regimen” est imand.  
Analysis of change fro m baseline in body weight at 52-week visit will be conducted in a manner 
similar to the primary  efficacy  analyses wi th change in body  weight from baseline as the 
response variable , baseline HbA1c category  
(≤8.5%, ˃8.5% ) in place of baseline HbA1c, and 
baseline body  weight as a covari ate.  
Com parisons am ong treatm ents relative to proportion of pat ients achieving HbA1c target value 
of <7.0% (53 mmo l/mol) at52-week visit will be conducted using a logist ic regression analysis 
with term s treatm ent, country, SGLT -2i use ( Yesor
No), and baseline HbA1c as a covariate .  In 
the anal ysis of patients achieving HbA1c target value relative to the “efficacy ”estimand, 
subjects wi th missing values at 52-week visit will be excluded.  In the analysis of patients 
achieving HbA1c target value relative to the “treatment -regimen ”estimand, m issing values at 
52-week visit will be imputed based on observed data at respective visits from patients in the 
same treatment arm who had thei r efficacy assessed after early discont inuat ion of study  drug 
and/or init iation of rescue medicat ion.  Analysis will be conducted with mult iple imputations and 
statist ical inference over mult iple imputations will be gu ided by the method proposed by Rubin 
(1987).  
10.3.3.3. Tertiary/Exploratory Analyses 
All exploratory  efficacy an alysis will be guided by “efficacy ”estimand and will be conducted 
using EAS.   
Details will be provided in the SAP.
10.3.4. Safety Analyses
Unless specified otherwise, s afety assessments will be guided by  an estimand co mpar ing safety  
of LY3298176 doses wi th insulin glargine irrespective of adherence to study  drug or ini tiation of 
rescue therapy . Thus, safet y analysis will be conducted using S afety Analysis Set.  Sel ected 
safet y analysis will be conducted after excluding data on rescue therapy .  
I 8 F -M C - G P G M( b) Cli ni c al Pr ot o c ol P a g e 6 9 
L Y 3 2 9 8 1 7 6 A d verse e ve nts will be c o de d fr o m t he act ual ter m usi n g t he Me dical Dict i o nar y  f or Re g ul at or y 
Act i vit ies ( Me d D R A) a n d re p orte d wit h preferre d ter ms a n d s yste m or ga n class.  Selecte d 
n ota bl e A Es of i nterest ma y be re p orte d usi n g hi g h -le vel ter ms or Sta n dar dize d Me d D R A 
Q ueri es .  S u m mar y  statistics will be pr o vi de d f or i nci de nce of T E A Es, seri o us a d verse e ve nts 
( S A Es), st u d y  di sc o nti n uati o n d ue t o A Es, st u d y dr u g disc o nt i n uat i o n d ue t o A Es , deat hs, a n d 
ot her C V e n d p oi nts.  C o u nts a n d pr o p orti o ns o f s u bjects e x perie nci n g A Es will be re p orte d f or 
eac h treat me nt gr o u p, a n d Fis her’s e xact test will be use d t o c o m pare t he treat me nt gr o u ps.  
1 0. 3. 4. 1. H y p o gl y c e mi c E v e nt s 
I nci de nce of d oc u me nte d s y m pt o mat ic h y p o gl yce mia e ve nts a n d se vere h y p o gl yce mia i n eac h 
cate g or y  ( ei t h er t otal  or n oct ur nal) will be c o m pare d bet wee n L Y 3 2 9 8 1 7 6 d oses a n d i ns uli n 
gl ar gi ne usi n g ne gat i ve bi n o mial re gressi o n a nal ysis . S u m m ari es a n d a nal ysis will be re peate d 
e xcl u di n g data f o ll o wi n g i nit iat i o n of resc ue a nt ih y per gl yce mic t h era p y .
1 0. 3. 4. 2. G a str oi nt e sti n al E v e nt s 
S u m maries a n d a nal yses f or i nci de nce a n d se verit y of na usea ,v o mit i n g ,a n d diarr hea will be 
pr o vi de d b y eac h treat me nt.  
1 0. 3. 4. 3. A dj u di c at e d C ar di o v a s c ul ar E v e nt s 
List i n g of deat hs, m y ocar dial i nfarct i o ns, str o kes, a n d h os pitalizat i o n f o r u nsta ble a n gi na 
c o nfir me d b y a n i n de pe n de nt C E C will be pr o vi de d. T he dates of ra n d o mizat i o n, e ve nt, first 
d ose a n d l ast d ose of st u d y  dr u g, a n d ti me fr o m  ra n d o mizat i o n t o e ve nt will be liste d.  
1 0. 3. 4. 4. C e ntr al L a b or at or y M e a s ur e s , Vit al si g n s, a n d El e ctr o c ar di o gr a m s 
Val u es a n d c ha n ge fr o m baseli ne t o p ost baseli ne val ue sof  ce ntral  l a b orat or y  m eas ures, vital 
si g ns, a n d s electe d E C G para meters will be s u m mari ze d at eac h sc he d ule d visit. The a nal ysis 
m o d el  t o m a ke c o m par is o ns a m o n g treat me nt ar ms relat i ve t o c o nti n u o us c ha n ge fr o m baseli ne 
val ues assesse d o ver ti me will  b ea n M M R M, wi t h ter ms: treat m e nt, visi t, a n d treat m e nt - b y- visit 
i nt eract i o n, c o u ntr y , baseli ne S G L T - 2i use ( Yes or N o), a n d baseli ne meas ure me nt as a 
c o vari ate. A n u nstr uct ure d c o varia nce str uct ure will m o del relati o ns hi p of wit hi n -pat ie nt  err ors. 
T he per ce nta ges of pat ie nt s wi t h  treat m e nt -e m er ge nt a b n or mal, hi g h, or l o w l a b orat or y  meas ures 
at a n y ti me will be s u m marize d a n d c o m pare d bet wee n treat me nt gr o u ps b y usi n g Fis her’s e xact 
test.  A treat me nt -e m er ge nt a b n or m al val ue is defi ne d as a c ha n ge fr o m n or m al  v al u e at baseli ne 
t o a n a b n or m al  v al u e at a n y  ti me d uri n g t he f o ll o w- u p. A treat me nt -e mer ge nt hi g h res ult is 
defi ne d as a c ha n ge fr o m a val ue less t ha n or e q ual t o t he hi g h li mit at baseli ne t o a val ue greater 
t h a n t he hi g h li mit at a n y  ti me d uri n g Peri o d s II, III, a n d I V . A treat me nt -e m er ge nt l o w res ul t i s 
defi ne d as a c ha n ge fr o m a val ue greater t ha n or e q ual t o t he l o w li mit at baseli ne t o a val ue less 
t h a n t he l o w li mit at a n y  ti me d uri n g Peri o ds II, III, a n d I V .  Hi g h li mit a n d l o w li mit will be 
pr o vi de d i n S A P. 
1 0. 3. 5. P h ar m a c o ki n eti c/ P h ar m a c o d y n a mi c A n al y s e s 
L Y 3 2 9 8 1 7 6 c o nce ntrati o n data will be a nal yze d usi n g a p o p ulat i o n P K a p pr oac h via n o nli near 
mi xe d -effects m o deli n g wi t h  t he N O N M E M s oft ware.  T he relati o ns hi ps bet wee n L Y 3 2 9 8 1 7 6 
d ose a n d/ or c o nce ntr ati o n a n d efficac y , t ol era bili t y , a n d safet y e n d p o i nt s will be c haracterize d. 
I8F-MC-GPGM(b) Clinical Protocol Page 70
LY3298176Addit ionally , the impact of intrinsic and extrinsic patient factors such as age, weight, gender, and
renal funct ion on PK and/or PD parameters may be examined as needed. If ant i-drug ant ibody
titers are detected from immunogenicit y testing, then the impact of immunogenicit y titers on 
LY3298176 PK or any  relevant PD param eters m ay also be examined.
10.3.6. Evaluation of Immunogenicity 
The frequency and percentage of patients with preexi sting ADA , with TEADA , and wi th 
neutralizing TEADA to LY3298176 will be tabul ated by LY3298176 dose.  Treatment -
emergent ADAs are defined as those with a titer 2- fold (1 dilut ion) greater than the minimum 
requi red dilut ion if no ADAs were detected at baseline (treatment -induced ADA) or those with a 
4-fold (2 dilutions) increase in titer compared to baseline if ADAs were detected at baseline 
(treatment -boosted ADA).   
For the TEADA patients ,the distributi on of  maximum  titers will  be 
described by LY3298176 dose. The frequency o f neutralizing ant ibodies to LY3298176 and/or 
cross -reactive and neutralizing ant ibodies to endogenous counterparts will be tabulated in TE
ADA+ pati ents.
The rel ationship between the presence of ant ibodies and the PK parameters and PD response 
including safet y and efficacy  to LY3298176 may be assessed.
10.3.7. Other Analyses
10.3.7.1. Health Economics 
Analyses of actual  and change fro m baseline in patient -reported outcome (PRO) scores will be 
conducted using linear models with baseline PRO scores, treatm entand other factors that may be 
considered relevant. These variables will be specified in the SAP .  
10.3.7.2. Subgroup Analyses 
Subgroup analyses of mean change in HbA1c from baseline to V isit 1 8 will be provide dby age, 
race, ethnicit y, gender, duration of diabetes, baseline HbA1c ( ≤8.5%, ˃8.5%), and baseline 
SGLT -2i use ( YesorNo).
10.3.8. Interim Analyses
No interim analyses of efficacy (eg, HbA1c and body weight) are planned for this study.  
Adata m onitoring committee (DMC) will have the responsibilit y to revi ew unblinded interim 
analysis results in order to monitor the safet y of the pati ents in the study .  A sponsor statist ical 
analysis group external to the study  team  will perform  the data analysis for the DMC.  As no 
efficacy  analyses are pl anned by  theDMC , the family -wise errorratefor the efficacy analysis of 
the current protocol will not be affected by any of these interim analyses; hence, no alpha 
spending is necessary .  The DMC will perform safety  review s peri odically.  Detailed informat ion 
regarding safety  reviews will  be described in the program DMC Charter.
Study  sites will receive informat ion about interim results ONLY if deemed necessary for the 
safet y of their pati ents.
I8F-MC-GPGM(b) Clinical Protocol Page 71
LY329817610.3.8.1. Interim Safety CV Analysis
This study  is designed to contribute approximately 110 patients with MACE -4 endpo int towards
the accrual of approxim ately 133 pati ents wi th MACE -4 endpoint demonstrati ng that 
LY3298176 treatment is not associated with excessive CV risk.  Interim analysis of the CV 
safet y meta -analysis is to be conducted when allthe following condi tions are m et:
1.At least 100 patients have reached MACE -4 endpoint confirmed by the CEC across 
all tri als included in the CV meta -analysis
2.All tri als included in the CV m eta-analysis SAPexcept for the current trial have 
achieved their database lock
3.All patients in the current trial who have not discont inued the study before 12 months 
complete the 12 -month primary  endpoint assessment
4.At least 300 patients in the current trial receive 18 m onths or l onger of exposure to
tirzepat ide
An interim data extraction fro m the current trial will be conducted when all the condi tionsabove 
are met to aid wit h the conduct of the interim safety  CV meta -analysis.  If the interim safety  CV 
meta -analysis results in discharging excessive CV risk with tirzepat ide, then close-out of the 
current tri al will be ini tiated regardless of number of patients wi th MACE -4 in this study .  If the 
interim safet y CV meta -analysis does not resul t in di scharging excessive CV risk with 
tirzepat ide, then the current trial willcontinue unt il approximately 133patients experi ence 
MACE -4 across all the tri alsincluded in the CV safet y meta-analysis.
I8F-MC-GPGM(b) Clinical Protocol Page 72
LY329817611. References
Albert i KG,Zimmet PZ. Definit ion, diagnosis and cl assificat ion of diabetes mellitus and its 
complicat ions. Part 1: diagnosis and classificat ion of diabetes mellitus provisio nal report of a 
WHO consultation. Diabet Med. 1998;15(7):539 -553.
[ADA] American Diabetes Associat ion. Glycemic Targets. Sec 6. In Standards of Medical Care 
in Diabetes -2017. Diabetes Care . 2017;40( suppl 1): S48 -S56. Available at:
http://care.diabetesjournals.org/content/40/Supplement_1/S48. Accessed June 04 , 2018.
[ADA] American Diabetes Associat ion Posi tion Statem ent: Standards of Medical Care in 
Diabetes -
2017 Diabetes Care . 2017; 40(Suppl . 1):S1 –S138. Available at:  
https://professio nal.diabetes.org/sites/professio nal.diabetes.org/files/media/abridged_standards
_of_medical_care_in_diabetes_2017_0.pdf   
Accessed September 17, 2018.
Aroda VR, Ratner R. The Safet y and tol erabili ty of GLP -1 recept or agonists in the treatment of 
type 2 di abetes : a revi ew. Diabetes Metab Res Rev . 2011 Sep;27(6):528- 42. 
Banks PA, Freeman ML. Practice guidelines in acute pancreatit is. Am J Gastroenterol .
2006;101(10):2379 -2400.
Basaglar [US package insert (USPI)]. In dianapo lis, IN: Eli Lilly  and Com pany; 2015. Available 
at: https://www.accessdata.fda.gov/drugsat fda_docs/label/2015/205692lbl.pdf.
Bradl ey C.The di abetes treatm ent satisfact ion questionnaire: DTSQ. In: Bradley C, editor.
Handbook of Psy chology and Diabetes: a guide to psychological measurement in diabetes 
research and practice. Chur, Swi tzerland: Harwoo d Academic Publishers; 1994.
Danne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A, Johnston P. A randomized trial 
comparing the rate of hypoglycemia – assessed using continuous glucose monitoring – in 125 
preschool children with ty pe 1 diabetes treated with insulin glargine or NPH insulin (the
PRESCHOOL study ). Pediatr Diabetes . 2013;14(8):593 -601. Erratum in: Pediatr Dia betes . 
2015;16(6):462.
EuroQoL Group. EQ -5D- 5L User guide : basic info rmation on how to use the EQ - 5D-5L 
instrum ent. Versi on 2.1. Available at: https://euroqol.org/wp -content/uploads/2016/09/EQ -5D-
5L_UserGuide_2015.pdf. Published April 2015 . Accessed May  03, 2018.
Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortalit y from coronary  heart di sease 
in subjects wi th type 2 di abetes and in nondiabet ic subjects with and without prior myocardial 
infarction. N Engl J Med .1998;339 (4):229-
234.
Hayes RP, DeLo zier AM. Reliabilit y, validit y, and responsiveness o f the Impact of  Weight on 
Self-Percept ions Questionnaire (IW -SP) in individuals with ty pe 2 diabetes and obesit y. 
Diabetes Technol Ther . 2015;17(3):210 -214.
Hayes RP, Nel son DR, Meldahl ML, Curtis BH. Abi lity to perform  daily  physical  activi ties in 
individuals wit h type 2 di abetes and m oderate obesit y: a preliminary validation o f the Impact 
of Wei ght on Activit ies of Daily Living Quest ionnaire. Diabetes Technol Ther . 
2011;13(7):705 -
712.
I8F-MC-GPGM(b) Clinical Protocol Page 73
LY3298176Hayes RP, Schul tz EM, Naegeli AN, Curtis BH. Test -retest, responsiveness, and minimal 
important change o f the abilit y to perform physical activit ies of daily living quest ionnaire in 
individuals wit h type 2 di abetes and obesit y. Diabetes Technol Ther . 2012;14(12):1118- 1125.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas 
A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a
patient- c entered approach: update to a position statem ent of  the Ameri can Diabetes 
Association and the European Associat ion for the Study  of Diabetes. Diabetes Care .
2015;38(1): 140-149.
Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, 
Kimura Y, Takeda K, Isaji S, Otsuki M, Matsuno S; JPN. JPN Guidelines for the m anagement 
of acute pancreatit is: diagnostic criteria for acute pancreat itis. J Hepatobiliary Pancreat Surg . 
2006;13(1):25 -
32.
Nauck M. Incretin therapies: highlight ing commo n features and differences in the modes of 
action of  glucagon -like peptide -1 receptor agoni sts and di peptidyl peptidase -4 inhibitors. Diab 
Obesity Metab. 2016;18:203 -216. 
Riddle MC, Rosenstock J, Gerich J ; Insulin Glargine 4002 Study  Investi gators . The treat -to-
target tri al: rando mized addit ion of glargine or human NPH insulin to oral therapy  of type 2 
diabetic pat ients. Diabetes Care .2003; 26(11):3080 -3086.
Rubin DB. Mult iple imputati on for nonresponse in surveys. New York: John Wiley & Sons Inc.;
1987.
Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD
, Nauck MA ;LEADER Steering 
Committee ;LEADER Tri al Invest igators. Amylase, lipase, and acute pancreat itis in people 
with type 2 diabetes treated with liraglut ide: results from the LEADER Rando mized Trial.
Diabetes Care .2017a ;40(7):966-972.
Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of 
liraglutide on amylase, lipase, and acute pancreat itis in part icipants wi th overwei ght/obesi ty 
and normoglycemia, prediabetes, or ty pe 2 di abetes: secondary  analyses of pool ed data from 
the SCALE clinical development program. Diabetes Care .2017 b; 40(7):839-848.
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequent lyrepeated gl ucose m easurements 
overestimate the incidence of inpatient hy poglycemia and severe hyperglycemia. J Diabetes 
Sci Technol . 2010;4(3):577 -582.
I8F-MC-GPGM(b) Clinical Protocol Page 74
LY329817612. Appendices
I8F-MC-GPGM(b) Clinical Protocol Page 75 
LY3298176  Abbreviations and Definitions Appendix 1.
Term Definition 
ADA anti-drug antibodies 
AE adverse event:  Any untoward  medical occurrence in a 
patient or clinical investig ation subject administered a 
pharmaceutical product that does not necessarily have a 
causal relationship with this treatment.  An adverse 
event can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), 
symptom, or disease tempora lly associated with the use 
of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. 
ALP alkaline phosphatase 
ALT alanine aminotransferase 
ANCOVA analysis of covariance 
APPADL Ability to Perform Physical Activities of Daily Living 
AST aspartate aminotransferase 
BG blood glucose 
BMI body mass index 
CEC clinical endpoint committee 
CHF congestive heart failure 
CI confidence interval 
CIOMS Council for International Organizations of Medical Sciences 
CKD chronic kidney disease 
CKD-EPI Chronic Kidney Disease-Epidemiology 
companion diagnostic  An in vitro diagnostic device (assay or test) that 
provides information that is essential for the safe and 
effective use of a corresponding therapeutic product 
I8F-MC-GPGM(b) Clinical Protocol Page 76 
LY3298176 complaint A complaint is any written, electronic, or oral 
communication that alleges deficiencies related to the 
identity, quality, purity, durability, reliability, safety or 
effectiveness, or performance of a drug or drug delivery system. 
compliance Adherence to all study-related, good clinical practice (GCP), and applicable regulatory requirements. 
COVID-19 Coronavirus Disease 2019 
CRF case report form 
CRP clinical research physician:  Individual responsible for 
the medical conduct of the study.  Responsibilities of 
the CRP may be performed by a physician, clinical 
research scientist, global safety physician, or other 
medical officer. 
CSR clinical study report 
CT computed tomography 
CV Cardiovascular 
CVD cardiovascular disease 
DMC data monitoring committee 
DPP-4 dipeptidyl-peptidase-4 
DTSQ Diabetes Treatment Satisfaction Questionnaire 
EAS efficacy analysis set 
ECG Electrocardiogram 
eCRF electronic case report form 
eGFR estimated glomerular filtration rate 
enroll The act of assigning a patient to a treatment.  Patients 
who are enrolled in the study are those who have been assigned to a treatment. 
enter Patients entered into a study are those who sign the informed consent form direct ly or through their legally 
acceptable representatives. 
EQ-5D-5L European Quality of Life 
ERB ethical review board 
ESRD end stage renal disease 
I8F-MC-GPGM(b) Clinical Protocol Page 77 
LY3298176 ET early termination 
FAS full analysis set 
FBG fasting blood glucose 
FSH follicle-stimulating hormone 
FTV final treatment visit 
GCP good clinical practice 
GI Gastrointestinal 
GIP glucose-dependent insulinotropic polypeptide 
GLP glucagon-like peptide-1 
HbA1c hemoglobin A1c 
IB Investigator’s Brochure 
ICF informed consent form 
informed consent A process by which a patient voluntarily confirms his 
or her willingness to participate in a particular study, 
after having been informed of all aspects of the study 
that are relevant to the patient’s decision to participate.  
Informed consent is documented by means of a written, 
signed, and dated informed consent form. 
interim analysis An interim analysis is an analysis of clinical study data, 
separated into treatment groups, that is conducted 
before the final reporting database is created/locked. 
INT International normalized ratio 
investigational product A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including products already on the market when 
used or assembled (formulated or packaged) in a way 
different from the authorized form, or marketed products used for an unauthorized indication, or 
marketed products used to gain further information 
about the authorized form. 
I8F-MC-GPGM(b) Clinical Protocol Page 78 
LY3298176 ITT intention to treat:  The principle that asserts that the 
effect of a treatment policy can be best assessed by 
evaluating on the basis of the intention to treat a patient 
(that is, the planned treatment regimen) rather than the actual treatment given.  It has the consequence that 
patients allocated to a treatment group should be 
followed up, assessed, and anal yzed as members of that 
group irrespective of their compliance to the planned 
course of treatment. 
IWRS interactive web-response system 
IW-SP Impact of Weight on Self-Perception 
MACE major adverse cardiovascular events 
MedDRA Medical Dictionary for Regulatory Activities 
MEN-2 multiple endocrine neoplasia type 2 
mITT modified intention-to-treat 
MMRM mixed-model for repeated measures 
MRI magnetic resonance imaging 
MTC medullary thyroid carcinoma 
OTC over the counter 
PK/PD pharmacokinetics/pharmacodynamics 
PRO patient-reported outcome 
QW once weekly 
SAD single ascending dose 
SAE serious adverse event 
SAP statistical analysis plan 
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 
SAS safety analysis set 
SC subcutaneous 
SD standard deviation 
screen The act of determining if an individual meets minimum 
requirements to become part of a pool of potential 
candidates for participation in a clinical study.  
I8F-MC-GPGM(b) Clinical Protocol Page 79 
LY3298176 SGLT-2 sodium-glucose co-transporter-2 
SGLT-2i sodium-glucose co-transporter-2 inhibitor 
SMBG self-monitored blood glucose 
SUSARs suspected unexpected se rious adverse reactions 
T1DM type 1 diabetes mellitus 
T2DM type 2 diabetes mellitus 
TBL total bilirubin level 
TE treatment-emergent 
TEAE treatment-emergent adverse event:  An untoward 
medical occurrence that emerges during a defined treatment period, having been  absent pretreatment, or 
worsens relative to the pretre atment state, and does not 
necessarily have to have a causal relationship with this 
treatment. 
TTT treat-to-target 
ULN upper limit of normal 
I8F-MC-GPGM(b) Clinical Protocol Page 80 
LY3298176  Clinical Laboratory Tests  Appendix 2.
Clinical Laboratory Testsa  
Hematology Clinical Chemistry 
Hemoglobin Serum Concentrations of: 
Hematocrit Sodium 
Erythrocyte count (RBC) Potassium 
Bicarbonate 
Mean cell volume Total bilirubin Mean cell hemoglobin concentration Direct bilirubin Leukocytes (WBC) Alkaline phosphatase 
Neutrophils, segmented Alanine aminotransferase (ALT) 
Lymphocytes Aspartate aminotransferase (AST) Monocytes Blood urea nitrogen (BUN) Eosinophils Creatinine Basophils Uric acid Platelets Calcium 
 Glucose, fasting 
Urinalysis  Albumin 
Albumin Cholesterol 
Creatinine Creatine kinase (CK) 
 
Nonpharmacogenetic Stored Samples 
 
Serum 
EDTA plasma P800 plasma Pregnancy Test  (females only)
b 
  
 eGFR (calculated by CKD-EPI equation)c 
  
 Pancreas (exocrine) 
 Serum pancreatic amylase 
HbA1c Serum lipase 
  Endocrine Immunogenicity 
Calcitonin LY3298176 anti-drug antibody 
Follicle-stimulating hormone  
  Anti-GAD Antibodies 
 Lipid Panel (fasting)  
   Total cholesterol 
   LDL 
 HDL 
Samples for PK analysis 
 Pharmacogentics Sample VLDL 
 Triglycerides   
I8F-MC-GPGM(b) Clinical Protocol Page 81 
LY3298176    
Abbreviations:  CKD-EPI = Chronic Kidney Disease-Epidem iology; eGFR = estimated gl omerular filtration rate; 
HbA1c = hemoglobin A1c; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein 
cholesterol; PK = pharmacokinetics; VLDL = very low-density lipoprotein cholesterol. 
a All tests will be performed by a Lilly-designated central laboratory, unless otherwise noted. 
b Serum pregnancy test will be performed by central laboratory at Visit 1 for women of childbearing potential; 
urine pregnancy tests may be performed at the investigator’s discretion during the study.  A local laboratory may 
be used for urine pregnancy tests. 
c Estimated glomerular filtration rate w ill be calculated by the central laboratory at all visits and included in lab 
result reports. 
 
I8F-MC-GPGM(b) Clinical Protocol Page 82 
LY3298176  Study Governance Considerations Appendix 3.
Appendix 3.1. Regulatory and Ethical  Considerations, Including the 
Informed Consent Process  
Appendix 3.1.1. Informed Consent 
The investigator is responsible for the following: 
 ensuring that the patient understands the na ture of the study, the potential risks 
and benefits of participating in the study, and that their participation is voluntary. 
 ensuring that informed consent is given by each patient or legal representative.  
This includes obtaining the appropriate si gnatures and dates on the informed 
consent form (ICF) prior to the performan ce of any protocol procedures and prior 
to the administration of investigational product. 
 answering any questions the patient may have throughout the study and sharing in 
a timely manner any new information that may be relevant to the patient’s 
willingness to continue his or her participation in the study. 
 ensuring that a copy of the ICF is provided to the participant or  the participant’s 
legal representative and is kept on file. 
 ensuring that the medical record include s a statement that written informed 
consent was obtained before the participan t was enrolled in the study and the date 
the written consent was obtained.  The authorized person obtaining the informed 
consent must also sign the ICF.  
Appendix 3.1.2. Recruitment 
Lilly or its designee is responsible for the cent ral recruitment strategy for patients.  Individual 
investigators may have additional local requirements or processes. 
Appendix 3.1.3. Ethical Review 
The investigator or an appropria te local representative must give assurance that the ethical 
review board (ERB) was properly constituted and convened as required by International Council 
for Harmonisation (ICH) guidelines and ot her applicable laws and regulations. 
Documentation of ERB approval of the protocol and the ICF must be provided to Lilly before the 
study may begin at the investigativ e site(s).  Lilly or its repres entatives must approve the ICF, 
including any changes made by the ERBs, before it is used at the investigative site(s).  All ICFs 
must be compliant with the ICH guideline on good clinical practice (GCP). 
The study site’s ERB(s) should be  provided with the following: 
 the protocol and related amendments a nd addenda, current Investigator Brochure 
(IB), and updates during the course of the study 
I8F-MC-GPGM(b) Clinical Protocol Page 83 
LY3298176  informed consent form  
 other relevant documents (for exampl e, curricula vitae, advertisements) 
 
Appendix 3.1.4. Regulat ory Considerations 
This study will be conducted in accordance with the protocol and with the following points: 
 consensus ethics principles derived from international ethics guidelines, including 
the Declaration of Helsinki and Council fo r International Organizations of Medical 
Sciences International Ethical Guidelines 
 applicable ICH GCP Guidelines 
 applicable laws and regulations 
Some of the obligations of the sponsor  will be assigned to a third party. 
Appendix 3.1.5. Invest igator Information 
Physicians with a specialty in diabetes/endoc rinology, cardiology, nephrol ogy, internal medicine, 
family medicine, general medicine , or any other specialty physici an who has experience treating 
Type 2 Diabetes  with clinical research experience will part icipate as investigators in this clinical 
trial. 
Appendix 3.1.6. Protocol Signatures 
The sponsor’s responsible medical officer will ap prove the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study. 
After reading the protocol, each principal investig ator will sign the protocol signature page and 
send a copy of the signed page to a Lilly representative. 
Appendix 3.1.7. Final Report Signature 
The clinical study report (CSR) coordinating investigator will si gn the final CSR for this study, 
indicating agreement that, to the best of his or her knowledge, the report a ccurately describes the 
conduct and results of the study. 
A qualified investigator will serve as the CSR coordi nating investigator.  If this investigator is 
unable to fulfill this function, another investigator  will be chosen by Lilly to serve as the CSR 
coordinating investigator. The sponsor’s responsible medical officer and st atistician will approve the final CSR for this 
study, confirming that, to the best of his or he r knowledge, the report accurately describes the 
conduct and results of the study. 
Appendix 3.2. Data Quality Assurance 
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following: 
I8F-MC-GPGM(b) Clinical Protocol Page 84 
LY3298176  provide instructional material to  the study sites, as appropriate 
 provide sponsor start-up training to instruct the investigators and study 
coordinators.  This training will give instruction on the protocol, the completion 
of the eCRFs, and study procedures 
 make periodic visits to the study site 
 be available for consultation and stay in contact with the study site personnel by 
mail, telephone, and/or fax 
 review and verify data reported to detect potential errors  
In addition, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study si te.  The study may be audited by Lilly or its 
representatives and/or regulatory agencies at any time.  Investigators will be given notice before 
an audit occurs. 
The investigator will keep records of all origin al source data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the investigator will provide the sponsor, 
applicable regulatory agencies, and applicable ERBs with direct access to original source 
documents. 
Appendix 3.2.1. Data Capture System 
The investigator is responsible for ensuring the accuracy, complete ness, legibility, and timeliness 
of the data reported to the sponsor.  
An electronic data capture system  (EDC) will be used in this st udy for the collection of the eCRF 
data.  The investigator maintains a separate sour ce for the data entered by the investigator or 
designee into the sponsor-provided EDC system.  The investigator is responsible for the 
identification of any data to be considered sour ce and for the confirmation that data reported are 
accurate and complete by signing the eCRF. Additionally, clinical outcome assessment (COA) data (questi onnaires, scales, self-reported diary 
data, rating scales, etc.) will be collected by the patient (investigator site personnel), via a paper 
source document and will be transcribed by the inve stigator site personnel into the EDC system. 
Data collected via the sponsor-provided data captur e system(s) will be stored at third party.  The 
investigator will have continuous access to th e data during the study and until decommissioning 
of the data capture system(s).  Prior to decomm issioning, the investigator will receive an archival 
copy of pertinent data for retention. Data managed by a central vendor, such as laborato ry test data, will be stored electronically in 
the central vendor’s database system, and electronic  transfers will be provided to the investigator 
for review and retention.  Data will subsequently  be transferred from the central vendor to the 
Lilly data warehouse. Data from complaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management system. 
I8F-MC-GPGM(b) Clinical Protocol Page 85 
LY3298176 Appendix 3.3. Study and Site Closure 
Appendix 3.3.1. Discontinuation of Study Sites 
Study site participation may be di scontinued if Lilly or its designee, the investigator, or the ERB 
of the study site judges it necessa ry for medical, safety, regulatory, or other reasons consistent 
with applicable laws, regulations, and GCP. 
Appendix 3.3.2. Discont inuation of the Study 
The study will be discontinued if Lilly or its designee judges it necessary for medical, safety, 
regulatory, or other reasons c onsistent with applicable laws, regulations, and GCP. 
Appendix 3.4. Publication Policy 
The publication policy for Study I8F-MC-GPGM is described in Clinical Trial Agreement. 
I8F-MC-GPGM(b) Clinical Protocol Page 86 
LY3298176  Hepatic Monitoring Tests for Appendix 4.
Treatment-Emergent Abnormality 
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may 
be required in follow-up with patients in consul tation with the Lilly, or its designee, clinical 
research physician. 
Hepatic Monitoring Tests 
Hepatic Hematology a Haptoglobin a 
Hemoglobin  
Hematocrit Hepatic Coagulation a 
RBC Prothrombin Time 
WBC Prothrombin Time, INR 
Neutrophils, segmented  
Lymphocytes Hepatic Serologies a,b 
Monocytes Hepatitis A antibody, total 
Eosinophils Hepatitis A antibody, IgM 
Basophils Hepatitis B surface antigen 
Platelets Hepatitis B surface antibody 
 Hepatitis B Core antibody 
Hepatic Chemistry a Hepatitis C antibody 
Total bilirubin Hepatitis E antibody, IgG 
Direct bilirubin Hepatitis E antibody, IgM 
Alkaline phosphatase  
ALT Anti-nuclear antibody 
AST  
GGT Alkaline Phosphatase Isoenzymes a 
CPK   
 Anti-smooth muscle antibody (or anti-actin antibody)
a 
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma-glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red blood cells; WBC = white blood cells. 
a Assayed by Lilly-designated or local laboratory. 
b Reflex/confirmation dependent on regulatory requirements and/or testing availability. 
I8F-MC-GPGM(b) Clinical Protocol Page 87 
LY3298176  World Health Organization Appendix 5.
Classification of Diabetes and Diagnostic Criteria 
Type 1 Diabetes:   Type 1 diabetes is judged to be pr esent when the classical symptoms of 
diabetes (thirst, polyuria, wasting and stupor, or  coma) are associated with readily detectable 
concentrations of glucose and ketone bodies in  the blood and urine.  Insulin treatment is 
necessary not only to control hyperglycemia but al so to prevent spontaneous ketosis and death. 
Type 2 Diabetes:   Type 2 diabetes, although often asymptomatic, may also present with 
classical hyperglycemic symptoms (thirst, pol yuria, weight loss), but despite hyperglycemia, 
ketone bodies are present in only low concentrations in the blood and urine.  Coma is rare in type 
2 diabetes but may result from extreme hypergly cemia and hyperosmolarity; lactic acidosis or 
ketoacidosis can also occur in fulminating illness (for example, severe infection or mesenteric 
artery thrombosis) due to an acute increase in insulin requirements, but spontaneous ketosis does 
not occur.  Some patients with type 2 diabetes  later progress to a state of absolute insulin 
deficiency (Alberti and Zimmet 1998).  
  
I8F-MC-GPGM(b) Clinical Protocol Page 88 
LY3298176  Classification of Contraceptive Appendix 6.
Methods 
Highly Effective Methods of Contraception: 
 Combined oral contraceptive pill and mini pill 
 NuvaRing 
 Implantable contraceptives 
 Injectable contraceptives (such as Depo-Provera®) 
 Intrauterine device (such as Mirena® and ParaGard®) 
 Contraceptive patch – ONLY women <198 pounds or 90 kg 
 Total abstinence (if this is their preferred and usual lifestyle) or in a same-sex relationship 
with no sexual relationship with males (as part  of their preferred and usual lifestyle).  
Note:  periodic abstinence (for exampl e, calendar, ovulation, symptothermal, 
postovulation methods), declarat ion of abstinence just for the duration of a trial, and 
withdrawal are not acceptable  methods of contraception 
 Vasectomy – for men in clinical trials 
Effective Methods of Contraception (must use combination of 2 methods): 
 Male condom with spermicide 
 Female condom with spermicide 
 Diaphragm with spermicide 
 Cervical sponge 
 Cervical cap with spermicide 
 
  
I8F-MC-GPGM(b) Clinical Protocol Page 89 
LY3298176  Management of Patients with Severe, Appendix 7.
Persistent Hyperglycemia during the Treatment 
Period 
Below are criteria for deciding when and how to intervene with patients who do not reach 
glycemic targets.  An additional therapeutic intervention should be considered in patients who 
develop severe, persistent hypergly cemia after randomization at the discretion of the investigator 
in accordance with American Diabetes Associ ation (ADA)/European Association for the Study 
of Diabetes (EASD) guidance (Inzucchi et al . 2015).  Rescue treatment with pramlintide, 
dipeptidyl peptidase-4 (DPP-IV) i nhibitors, or glucagon-like peptide-1 (GLP-1) receptor agonists 
will not be allowed.  Rescue medication will be prescribed as add-on to randomized treatment 
and patients will continue to follow the protocol-specified visit schedule.   
 
Add-on glycemic rescue therapy will be allowed for patients based on the following criteria:   
1) The patient is fully compliant with the assigned therapeutic regimen 
AND 
2) has no acute condition that raises blood glucose 
AND 
a) average daily blood glucose (BG) from the once-weekly 4-poin t self-monitored BG 
(SMBG) profile >270 mg/dL (>15.0 mmol/L) ove r at least a consecutive 2-week period 
any time during the first 8 weeks postrandomization;  
OR  b) average daily blood glucose from the once-weekly 4-point SMBG profile >240 mg/dL 
(>13.3 mmol/L) over at least a consecutiv e 2-week period at any time 9-16 weeks 
postrandomization;  
OR c) average daily blood glucose  from the once-weekly 4-point SMBG profile >200 mg/dL 
(>11.1 mmol/L) over at least a consecutive 2-week period at any time beyond the first 
16 weeks postrandomization. 
OR 
d) HbA1c ≥8.5% (69 mmol/mol) on 2 consecutive measurements separated by at least 
8 weeks at any time beyond the first 24 weeks post randomization 
 
In the insulin glargine arm, the first step will be further titration of the insulin based on the 
corresponding Treat to-Targe t algorithm (until Week 16). 
I8F-MC-GPGM(b) Clinical Protocol Page 90 
LY3298176  Changes to Study Procedures due to Appendix 8.
the COVID-19 Pandemic 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the novel 
COVID-19 pandemic, has caused numerous global rest rictions to be enacted that may impact a 
patient’s ability and/or willingness to attend their onsite study visit as originally scheduled.  In 
such a situation, please follow the guidance below: 
1) Patients should come for the primary endpoint visit (Visit 24) at th e originally planned 
52-week (±7 days) schedule whenever possible and safe to do so, at the investigator's 
discretion.  However, in order to maximize the ability for onsite visits for Visit 24, 
minimize missing data, and preserve the intende d conduct of the study, the visit window 
for Visit 24 may be brought forward no sooner than 14 days (Week 50) or extended up to 
8 weeks (Week 60).   
2) The sites will need to identify and document the details of how all patients and visits 
were affected by the COVID-19 pandemic restrictions.  
3) Mobile (in home) healthcare visits may be  performed at participants’ homes when 
participants cannot travel to the site due to  extenuating circumstances.  These will be 
performed by a qualified home nursing servic e provider following sponsor approval, if 
permitted by local regulations.  Procedures pe rformed may include, but are not limited to, 
taking blood samples, conducting physical assessments, administering PROs, and 
collecting health information.  Please note that requirements related to the reporting of SAEs remain unchanged.  Every effort should be made for the partic ipant to return to 
onsite visits as soon as reasonably possible, while ensuring the safety of the participant and investigational site staff. 
4) Additional consent from the participant will be obtained for those who participate in 
home health services. 
 
I8F-MC-GPGM(b) Clinical Protocol Page 91 
LY3298176  Protocol Amendment I8F-MC- Appendix 9.
GPGM(b) 
Efficacy and Safety of LY3298176 Once Weekly 
versus Insulin Glargine in Patients with Type 2 
Diabetes and Increased Cardiovascular Risk 
(SURPASS-4) 
Overview 
Protocol I8F-MC-GPGM Efficacy and Safety  of LY3298176 Once Weekly versus Insulin 
Glargine in Patients with Type 2 Diabetes and Increased Cardi ovascular Risk (SURPASS-4) has 
been amended.  The new protocol is indicated by amendment (b) and will be used to conduct the 
study in place of any precedi ng version of the protocol. 
The overall changes and rationale for the changes made to this protocol are described in the 
following table.  Note that minor edits have been made throughout the protocol, which are not 
captured in the amendment summary table.
I8F-MC-GPGM(b) Clinical Protocol Page 92 
LY3298176 Amendment Summary for Protocol I8F-MC-GPGM Amendment (b) 
Section # and 
Name Description of Change Brief Rationale 
Section 2 Schedule of Activities Added a final treatment visit (FTV) and corresponding activities related 
to this visit Addition of this visit will allow consistent collection 
of data as patients complete the treatment period.
 
Section 5.1 Overall Design Changed visit numbers for the postrandomization period and Study Period III (variable treatment period) Correction/clarification. 
Section 5.1 Overall Design Added language related to the FTV Addition of this visit will allow consistent collection 
of data as patients complete the treatment period. 
Section 10.3.8 Interim Analyses Added language for a Safety Interim Analysis for the program wide 
MACE-4 Meta-Analysis Based on regulatory interaction. 
Appendix 8 Added language describing changes 
to the study procedures due to the 
COVID-19 pandemic The added language provides guidance when a patient’s ability and/or willingness to attend their onsite study visit is impacted by the global 
restrictions enacted in response to the COVID-19 
pandemic. 
 
Leo Document ID = a5cbc2ab-abd6-41f1-9bc9-b4fb6b412699
Approver: 
Approval Date & Time: 10-Jul-2020 15:14:01 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 10-Jul-2020 15:42:01 GMT
Signature meaning: Approved
PPD
PPD